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ABSTRACT
MOLECULAR MECHANISMS OF HOST RESTRICTION AND ADAPTATION
OF HANTAVIRUSES
Ryan C. McAllister
October 25, 2013
Hantaviruses, family Bunyaviridae, are present throughout the globe in a
variety of mouse, rat, mole, vole, shrew, or bat species. Hantaviruses persist for
the lifetime of the animal reservoir, while causing no signs or symptoms of
disease. Only the rodent-borne hantaviruses cause disease in humans. In
contrast, a “spillover” infection of a hantavirus into a nonreservoir rodent species
results in an asymptomatic acute infection. We and others in the field are
interested in understanding the biology of these virus-host interactions and
mechanisms that underlie these three very different outcomes.
The second chapter of my thesis focused on probing the intrahost viral
population structure of the Hantaan virus (HTNV), an Old World hantavirus, in the
suckling mouse model in the presence and absence of ribavirin. This model
represents a lethal disease outcome in a nonreservoir species. These studies
show, for the first time, two distinct evolutionary trajectories for HTNV within this
lethal mouse model of disease in the presence and absence of ribavirin, as well
as evidence for positive selection not previously observed in vitro. In the ribavirintreated vRNA population, analyses of rates of nonsynonymous (dN) and
iv

synonymous (dS) substitutions in the S-segment revealed a positive selection for
codons within the HTNV N protein gene, while untreated, HTNV-infected mice
showed purifying selection.
The third chapter of my thesis focused on development of a
physiologically relevant, in vitro model of the hantavirus-rodent reservoir
interaction; specifically, the deer mouse (Peromyscus maniculatus) and Sin
Nombre virus. As the primary target of hantaviral infection is the vascular
endothelium, a primary lung microvascular endothelial cell (L-MVEC) culture
system was established. Culture conditions were established and optimized for
passage and infection. Future research will use this model to probe viral
determinants and mechanisms that promote persistence and identify host
responses that pose barriers to virus adaptation.
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CHAPTER I
HANTAVIRUSES PAST, PRESENT, AND FUTURE

An introduction to the discovery of hantaviruses and their diseases
Historical retrospectives of medical reports suggest trench nephritis in the
first World War, nephropathia epidemica (NE) in Scandinavia, Song‐go fever in
Manchuria and hemorrhagic nephroso-nephritis in the Soviet Union were all
potentially caused by hantaviruses [1-4]. However, it was not until Hantaan virus
(HTNV) was isolated in 1977 that two human diseases were attributed to
hantaviruses; hemorrhagic fever with renal syndrome (HFRS) in Europe and
Asia, and NE, a mild form of HFRS, in northern Europe. Four Hantavirus species
are now recognized to cause HFRS (HTNV harbored by Apodemus agrarius [1];
Dobrava-Belgrade virus (DOBV) is harbored by A. agrarius. A flavicollis, and A.
ponticus rodents [5, 6]; Seoul virus (SEOV) is harbored by Rattus norvegicus [7])
and NE (Puumala virus, PUUV, harbored by Myodes glareolus).

Combined

these viruses have a global public health impact estimated at over 50,000 cases
each year with lethality ranging from 1 to 12% [8].
The wide prevalence of hantaviruses in rodents in Europe and Asia
suggested they could be potential reservoirs for hantaviruses in the Americas. In
the mid-1980’s rodent surveillance efforts discovered Prospect Hill virus (PHV)
harbored by Microtus pennyslvanicus [9], and cross reactive antibodies were
1

reported in Peromyscus maniculatus, P. difficilis, P. californicus, Neotoma
mexicana, N. cinerea [10] in the USA, and in Old World (laboratory) rodents in
South America [11]. It was not long after these efforts that an outbreak of
hantavirus pulmonary syndrome (HPS) in persons residing in the Four Corners
area in the southwestern USA in 1993 confirmed the presence of disease
causing hantaviruses in the Americas.
In the Spring of 1993, two young, healthy adults living in the Navajo Nation
fell ill and died from an unexplained adult respiratory distress syndrome (ARDS)
[12]. Unexplained deaths are reported to the Office of the Medical Investigator
(OMI) in New Mexico. Discussions between the OMI and the Indian Health
Service quickly recognized there were at least five cases of ARDS in the region.
The outbreak led to collaborative investigations by state health departments in
Arizona, Colorado, New Mexico, and Utah; the Indian Health Service; the OMI,
the University of New Mexico, and the Center for Disease Control (CDC), with
the assistance of the Navajo Nation Division of Health to identify cases, rodent
reservoirs and develop diagnostic and treatment approaches. Within a year’s
time, the CDC identified the causative agent as Sin Nombre virus (SNV)
harbored by Peromyscus maniculatus [13], a New World rodent species, and one
of the rodents reported having antibodies to hantaviral antigens in 1985 [10].
Other groups also reported the identification of SNV [14] and SN-like viruses
from patients and a number of other rodent reservoirs [8, 15].
Just two years after the outbreak in the USA, outbreaks of HPS were
recognized in Argentina and Chile caused by Andes virus (ANDV) [16-18], and in
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Paraguay caused by Laguna Negra virus (LANV) [19, 20]. In Paraguay, the
outbreak was associated with those living in the agricultural communities within
the Chaco. In contrast to the severity of disease and high mortality (50%) caused
by ANDV, the disease caused by LANV shows a lower mortality (<15%) [21]. In
the third outbreak in El Bolson, Argentina in 1996 [22], one physician in Buenos
Aires fell ill 27 days after taking care of an HPS patient from El Bolson [23]. This
was the first recognition that these viruses may cause person to person
transmission of the illness. Since that report, additional studies have shown that
person-to-person transmission can occur between couples, persons who sleep in
the same bed or room of index patients with ANDV infection, or sustained contact
during travel (e.g., on a bus) [23-26].

Coding and replication strategy of the Hantavirus genome
Hantaviruses, family Bunyaviridae, are negative-sense, single-stranded
RNA viruses with three gene segments (or viral RNAs, vRNAs): small (S),
medium (M) and large (L) [27]. The S-segment encodes for the nucleocapsid (N)
protein, the M-segment encodes for the GN and GC glycoproteins, and the Lsegment encodes for the RNA dependent RNA polymerase (RdRp). In the Ssegment of the hantaviruses carried by Arvicolinae and Sigmodontinae, but not
Muridae rodents, the N protein has an overlapping (+1) open reading frame for a
small, nonstructural protein (NSs) [28, 29]. The ends of each segment of the
genome have conserved, inverted, complementary 5' and 3' termini structure that
can form a panhandle [30, 31], which has been shown with other viruses in the
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Bunyaviridae [32, 33]. This region of the genome may contain cis-acting
elements that promote replication of the viral RNA (vRNA), complementary RNAs
(cRNAs) and messenger RNA (mRNA) transcription by the RdRp [30, 31]. The N
protein packages each of the three vRNA into three ribonucleoprotein (RNP)
complexes which are contained within the virus [8]. By cryoelectron microscopy
(Cryo-EM), the virion contains three to four rod-like RNP structures [34, 35],
which presumably contain each vRNA wrapped in N proteins. The viral
polymerase would be expected to be part of the RNP.
Reverse genetic approaches have been successful for other members of
the Bunyaviridae [36-39], but success in applying these strategies to
hantaviruses has been limited [40]. At present there has been no progress in the
creation of systems for the generation of infectious, recombinant hantaviruses.
The challenges in generating recombinant systems for the study of hantaviruses
may be due to the ability to produce the correct structures of the tripartite
genomes, which have a 5-prime monophosphate [41] or additional unknown
structural features.

Structure and function of hantaviral proteins
Hantavirus virions are asymmetric, pleomorphic particles, and until
recently were thought to have an average diameter of approximately 80-120 nm
[8, 42]. Electron microscopy studies of the HTNV and Tula virus (TULV) virions
now show the particles range in size from 120-154 nm [34, 35]. The surface
rendering of the virion suggests an unusual square, grid-like pattern distinct from
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other genera in the Bunyaviridae and a lack of icosahedral symmetry typical of
most viruses. The square spike on the outer surface reflects the glycoprotein
projections, which extend from 0 to 12 nm from the lipid bilayer and comprise 4
molecules of GN and GC [34].
Hantaviruses bind epithelial and endothelial cells via interaction of G N with
the host’s cell surface receptor(s); 1 integrin for apathogenic and 3 integrin for
pathogenic hantaviruses (Figure 1, step A) [43, 44]; although additional
receptors or co-receptors may also promote entry such as the decay-accelerating
factor (DAF/CD55) and the globular head domain of complement Clq [45]. In
addition, hantaviruses infect macrophages, follicular dendritic cells, and
lymphocytes [45-49]. In Vero E6 cells, HTNV has been shown to enter through
clathrin coated pits and traffic to late endosomes (Figure 1, step B) [50]. ANDV
do not enter via clathrin; the pathway for entry is not known [51]. Further, early
entry events are distinct for HTNV and ANDV given their difference in the
dependence on an intact actin (ANDV) versus microtubule (HTNV) cytoskeleton
for viral replication [51]. Release of the RNP's into the host cell cytoplasm from
endosomal compartments is pH dependent [50].

5

Figure 1. Hantavirus life cycle. The virus life cycle includes: (A) Attachment to
either β1 or β3 integrin of the host cell surface using the viral G N protein; (B)
Entry of the virus through clathrin receptor mediated endocytosis; (C)
Transcription via the RdRp cleaves host cell mRNA caps as primers for the
vRNA; (D) Translation of the N and RdRp proteins on free ribosomes and Msegment through rough ER; (E) Replication of vRNA requires N protein to form
the RNP; (F) Assembly of the virion at the Golgi or possibly for New World at the
plasma membrane; (G) Egress from the Golgi through the plasma membrane.
Reproduced from Future Virology. (2014) 9(1), 87-99 with permission of Future
Medicine Ltd.
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Homology modeling first suggested that the GC has a structure similar to
the alphavirus E1, which like GC, harbors the fusion domain [52]. The alphavirus
E1 is a class II fusion protein that forms a pH dependent, trimeric configuration to
mediate fusion with the host cell membrane within endosomes. A class II fusion
peptide maps to the GC protein, and has been shown to promote fusion using
ANDV GN/GC-pseudotyped lentiviral particles [52, 53]. With the recent Cryo-EM
of HTNV and TULV, elucidation of the structure of the glycoproteins and mapping
them within the Cryo-EM structures will shed light on how these GN/GC proteins
change conformationally to promote membrane fusion.
While the precise site(s) for viral transcription and replication are not
known, the RdRp protein transcribes viral mRNAs from each vRNA in the
cytoplasm using primers derived from host cellular mRNAs (Figure 1, step C)
[54]. The RdRp catalyzes the endonucleolytic cleavage of host cell mRNA at 718 nucleotides downstream from the 5' cap, this activity is also termed "cap
snatching" [54]. This results in hantaviral mRNAs with heterogeneous 5’-ends,
which are not polyadenylated. Translation of the S and L mRNAs occurs on free
ribosomes resulting in the production of the N and RdRp proteins; and NSs in
some hantaviruses (Figure 1, step D). The N protein, which accumulates in the
perinuclear region, is the most abundant viral protein synthesized early in
infection. N plays structural and functional roles in the virus life cycle including
modulation of host responses, binding to vRNA, cRNA and host mRNA caps,
translation initiation and assembly [31]. The timing and location at which N
protein apparently commanders the host mRNA caps is not known, but the N has
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been proposed to retain the caps in P bodies [55]. How these complexes traffic
from the P body to the replication complex(es) is not known. While not much is
yet known about the NSs, the TULV NSs localizes within the perinuclear region
[56]. It is highly likely that different oligomeric states or conformations of N occur
during the life cycle as demonstrated by their ability to form trimeric structures
[57, 58]. While not much is yet known about the NSs, the TULV NSs have been
reported to localize within the perinuclear region [56].The M-segment is
cotranslated into the rough endoplasmic reticulum (RER) (Figure 1, step D).
Following translation into the ER, the precursor protein is proteolytically cleaved
at a WAASA conserved amino acid motif located from amino acids, 264-268, into
GN and GC. A small portion of the c-terminus of the GN extends into the cytoplasm
(referred to as the GN tail). The GN and GC proteins are glycosylated in the RER
and translocate though the Golgi complex until they assemble into particles. The
GN cytoplasmic tail has been shown to bind to nucleic acid [59] and N protein
[60]. At some point following mRNA transcription, the RdRp begins replication of
the cRNAs and vRNAs (Figure 1, step E). The signals that initiate replication
are not known, however, it has been suggested that some level of N protein in
the cell could drive the switch. The N protein traffics by microtubule dynein to the
ER-Golgi Intermediate Complex (ERGIC) where they may begin to complex with
newly synthesized vRNAs to form RNPs [61].
It is unclear where or how the assembly of the RNP takes place, however,
at least in the case of the Old World hantaviruses, the RNPs must traffic to the
Golgi since this is the compartment where GN and GC glycoproteins are directed
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and virions have been visualized (Figure 1, step F) [62]. The RNP may interact
with the GN cytoplasmic tail [60] and buds into the Golgi to produce the virion. A
Golgi vesicle forms around newly formed particles and transports the virion to be
released from the host cell plasma membrane. Alternatively, for the New World
hantaviruses, it has been suggested that assembly could also take place at the
host cell plasma membrane (Figure 1, step F). This prediction was initially based
on the absence of virions within the Golgi for SNV and Black Creek Canal viruses
(BCCV). There is still limited evidence for where assembly takes place, however,
the glycoproteins of BCCV have been shown to be expressed at the plasma
membrane on the apical surface of polarized Vero C1008 cells [63]. Further,
studies by Rowe et al., have shown that the ANDV associates with the recycling
endosome and the Rab 9/11 proteins and this may serve as an important
pathway for trafficking from the Golgi to the plasma membrane [64].

Differential immune responses in rodents and humans
The survival of hantaviruses in nature depends on maintenance of
persistent infections within its specific rodent reservoir. Hantaviruses infect and
persist only in the rodent reservoir in which the virus has coevolved (monitored
through phylogenetic trees using sequences from reservoir host mitochondria
compared to hantavirus S-segment), and the infection is believed to last the life
of the animal [65]. Notably, persistent infection of rodent reservoirs by
hantaviruses show continuous virus replication, without complete clearance by
the immune system, and no pathological changes [8]. Humans are not a natural
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reservoir and therefore only become infected when they come into contact with
excreta from the rodent reservoir. In humans, infection can result in severe
disease although outcomes vary with different hantaviral species. There are also
a number of hantaviruses that do not appear to replicate in human endothelial
cells (PHV) [66] and/or cause disease in humans (TULV and PHV). The
molecular basis for this has been attributed to difference in receptor preferences
of apathogenic and pathogenic hantaviruses, which will be discussed later.
The clinical course and pathology of HFRS and HPS has been the subject
of several excellent recent reviews [67, 68]. It is recognized that both HFRS- and
HPS-causing hantaviruses cause systemic vascular leakage without apparent
damage to the endothelial cells even though the target organs for HFRS and
HPS differ, kidneys and lungs, respectively. In severe cases, this can lead to
hypotension and shock. Mechanisms proposed for the increase in capillary
leakage include infection-induced increase in vascular endothelial growth factor
(VEGF), and immunopathology (indirect through cytokines released by T cells). It
has been hypothesized that the immune response to hantavirus infection in
human

cases

causes

the

severe

disease

thrombocytopenia, increased leukocytes) [69].

symptoms

(e.g.,

acute

A recent study reports a third

mechanism for promotion of vascular leakage and disease. Using a novel in vitro
capillary blood vessel model, HTNV or ANDV infection increases bradykinin (BK)
through activation of the kallikrein-kinin system, which correlates with an increase
in endothelial cell permeability [70]. The capillary blood vessel model cocultured
human umbilical vein endothelial cells with human mesenchymal stem cells or
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human pulmonary artery smooth muscle cells, which generate blood vessel like
capillary structures. BK is an inflammatory peptide that can cause vasodilation
and vascular permeability in the vasculature upon binding of its receptor.
Interestingly, the model showed an increase in VEGF following infection, but no
loss in vascular integrity. The immune responses in humans following infection
with HPS and HFRS-causing viruses have been extensively reviewed [67, 69,
71-75]; therefore, in the following, we will highlight those responses that
distinguish between infections of the rodent reservoir and humans.
In Hantavirus infection, the differences in immune responses between
reservoir and humans are evident in composition, magnitude and kinetics of
cytokine/chemokine responses and T cells. Generally, longitudinal studies of
hantaviral infection show elevated TNF-α, IL-6, IL-2, IL-1 IL-10 IL-12 and
cytotoxic T lymphocytes (CTL) responses (Figure 2) [76-80]. Levels of secreted
cytokines and chemokines in deer mice infected with SNV cannot be compared
directly, as many antibodies are not yet available. However, longitudinal studies
of RNA levels of key cytokines and chemokines in lung and spleen have been
reported in SNV infected deer mice [81] and SEOV-infected rats [82]. While most
responses noted in humans were very low in SNV-infected deer mice (<twofold
above uninfected mice) and variable, IL-12 rose at 7 days post infection (dpi) in
the spleen. In addition, immune responses included increased GM-CSF (10 dpi)
and TGF-β (biphasic peaks at 5 and 15 dpi) in the spleen. The lack on
inflammatory signals was similar in SEOV infected rats; however, TGF-β was
elevated in the lungs, not spleen [82].
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Patients with severe HPS or HFRS/NE show strong CD8+T cell responses
with high levels of perforin and granzyme B [79, 80]. From these studies it has
been hypothesized that the strong CD8+ T-cell responses will eliminate virus, but
that such intensive T-cell responses might also result in an excessive amount of
cytokines, which promote capillary leakage and endothelial cell dysfunction [69,
73]. In contrast to these findings, a recent study of HFRS patients shows that the
prevalence of N-antigen-specific CD8+ T cells correlated with the early, acute
stages of infection and declined thereafter [83]. Hence, the CD8+T cells would be
expected to have a protective effect rather than promote immune pathology. In
support of these findings, T-cell-deficient Rowett nude rats infected with SEOV
succumb rapidly to infection and disease, suggesting that cell-mediated immunity
may play an important role in controlling infection [84]. More recently, the
depletion of T cells from hamsters did not alter the progression of HPS following
ANDV challenge, which suggests that vascular permeability does not involve Tcell-mediated immunopathology [85]. In summary, the present literature reports a
role for CTLs in promoting disease or protection; hence a more comprehensive
analysis of the CTL response is needed in many more patients. However, these
studies may be confounded in that most of the hantavirus-specific CTLs may be
present in organs and not accounted for during analyses of CTLs from peripheral
blood mononuclear cells (PBMC). An additional complexity is in the recent finding
that endothelial cells infected in vitro with ANDV and HTNV are protected from
CTL- and NK-cell-mediated apoptosis [86].
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Figure 2. Cellular players and responses in rodent reservoir and human
infections with hantaviruses. While there are many gaps in our understanding
of the role of the key immune cells and their function, recent studies suggest
several key immune responses. During a persistent infection reservoir species
have up regulated Protein Dependent Ligand 1 (PD-L1) and TGFβ resulting
regulatory T cells (Treg) response, which results in suppressed immune state.
IgG antibodies are produced suggesting a CD+4 T cell response. Whereas in
humans, pro-inflammatory cytokines such as TNFα, IL6, and IL10 are induced as
well as CD+8 and CD+4 T cells. Reproduced from Future Virology. (2014) 9(1),
87-99 with permission of Future Medicine Ltd.
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Mouse models of transient and persistent infection for HTNV have been
used to analyze the immune response of virus-specific CD8+ T cells with major
histocompatibility complex (MHC) tetramers [87, 88]. In persistently-infected
mice, N-specific CTLs are strongly regulated and were suppressed in the model
by an unknown mechanism [88]. Viral replication in immune cells such as
monocytes, macrophages or T cells can interfere with or actively suppress
immunity and cause persistence. Hence Taruishi et al, 2007 proposed that the
infection of the spleen early in infection may result in infection of immune cells
that suppress this response. In their persistent animal model experiments, the
infection of the spleen correlates with changes in CTL responses. Consequently,
due to the down-regulation of the CTLs, some of the endothelial cells may remain
infected, resulting in a persistent infection in the natural reservoir.
Studies of persistent infection of SEOV in the rat [89, 90] and SNV in the
deer mouse [91] suggest a role for regulatory T cells, Treg, in establishing
persistence. The Treg cells are Forkhead box (Fox) P3+CD4+CD25+ and are
activated during infection of the reservoir. In contrast, these cells are reduced in
HFRS patients [92], although they show no chang in PUUV-infected HFRS
patients [92]. The Treg responses can enable a persistent infection by limiting T
helper cell responses (TH1, TH2-cell) indirectly by modulating antigen-presenting
cell (APC) function or directly by cell–cell contact. The production of antiinflammatory cytokines (e.g., TGF-β and IL-10) by Treg can suppress innate
immunity and pro-inflammatory responses, and thereby interfere with viral
clearance and pathology [93]. Interestingly, in human cases of HFRS, higher IL-
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10 correlated with higher viral load [78]. In rat macrophages infected with SEOV,
nuclear factor-kappaB (NFkB)-mediated inflammatory responses noted in
patients (TNF-α, IL-6, and IL-10) are suppressed [82, 94]. Interestingly, SEOV
induces PD-L1 expression in rat endothelial cells and TGF-β in alveolar
macrophages [49] (Figure 1). The PD-1-PD-L1 pathway has been correlated
with increased Treg activity and also shown to play an important role in other
chronic viral infections such as Human Immunodeficiency virus (HIV), Hepatitis B
virus (HBV), Hepatitis C virus (HCV) and lower respiratory infections [95-97].

Hantaviral mechanisms in regulation of nonreservoir host immune
responses
While gaps remain in our understanding of how hantaviruses regulate the
immune responses at the molecular level, studies have suggested that viral N
(Figure 3) and glycoproteins may interact with host cellular proteins to modulate
the innate immune signaling. While gaps remain in our understanding of how
hantaviruses regulate the immune responses at the molecular level, studies have
suggested that viral N and glycoproteins interact with host cellular proteins to
modulate the innate immune signaling (Figure 3). Four different cellular
pathways have been implicated as targets of hantaviral antagonism in primate or
human cell models of infection; IFN-α/β responses (see reviews [71, 98, 99]),
JAK/STAT, TNF-α receptor-mediated signaling, and apoptosis [100]. Highlights
of what are currently known regarding hantaviral N, N proteins s and/or
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glycoproteins (GPCs) in modulation of these cellular activities will be summarized
in the following.
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Figure 3. Molecular interactions of N protein. Shown in the figure is the
suppression of the immune response during pathogenic hantaviruses infection
and hantaviral proteins. The N protein inhibits NFκB’s transport to the nucleus by
binding importin-alpha proteins and NFκB complex (1); or importin-alpha proteins
alone (2). The N protein can be cleaved by caspase 3 (3). The N protein is has
been shown to be required for JAK/STAT signaling suppression and (4) type I
IFN induction for some hantaviruses. The glycoprotein has also been shown to
be involved in suppression of Type I IFN induction through TBK1 (6) and
suppression of JAK/STAT signaling (7). Reproduced from Future Virology.
(2014) 9(1), 87-99 with permission of Future Medicine Ltd.
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Differences in which proteins are used by hantaviruses to inhibit
amplification of IFN responses have been reported. Moreover, differences in
induction of IFN-β RNA and protein have been shown following infection of
human microvascular endothelial cells by ANDV (pathogenic) or PHV
(nonpathogenic) [101]. ANDV suppressed IFN-β induction while PHV induced its
activation; however, both viruses suppressed STAT1/2 phosphorylation and
translocation [101]. Levine et al. showed that ANDV uses GPC and N protein to
suppress IFN-β induction and IFN-dependent JAK/STAT signaling [75]. In that
same report, SNV uses the GPC, but not N protein, to suppress IFN-β induction.
In studies of the New York virus (NYV), a pathogenic, New World hantavirus
closely related to SNV, the Gn-CT blocks RIG-I/TBK1 activation of IFN sequence
regulatory element (ISRE) transcriptional responses, but the PUUV Gn-CT did
not [66]. The NYV Gn-CT coprecipitates the N-terminal domain of TRAF3 [102].
The interaction of the NYV Gn-CT with TRAF3 is suggested to disrupt the
formation of TRAF3–TBK1 complexes and inhibit induction of IFN-β [102].
Interestingly, the Gc-CT TULV, but not PHV, inhibit IFN-β and ISRE induction
through TBK1, but not via TRAF3 [110]. Finally, the N protein of TULV has also
been reported to be a weak antagonist of IFN-β induction [28]. Finally, HTNV has
been shown to activate the Type III IFN, IFN-λ1, through a mechanism
independent of Type I IFN [103].
In addition to suppression of IFN and JAK/STAT, the N protein downregulates TNF-α receptor-mediated signaling by inhibiting activation of NFκB
[104-107]. Studies in 293T cells suggest that the HTNV N, but not ANDV or
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PUUV N, can block activation of NFκB by binding the importin-alpha proteins,
which are responsible for NFκB’s transport into the nucleus [107]. In a study by
Ontiveros et al., it was suggested that N may bind to both NFκB and importin as
a complex to prevent its nuclear translocation [106]. Both studies also show that
TNF-α induces degradation of IκB, implicating the block at NFκB’s transport.
Inhibition of signaling pathways normally leading to activation of caspases
and apoptosis is evident in cells expressing HTNV N protein [106] and ANDV N
protein [86]. Furthermore, ANDV and HTNV-infected endothelial and epithelial
cells are protected against staurosporine induced apoptosis [86, 106] and against
cytotoxic granule-mediated induction of apoptosis [86]. Intriguingly, the
suppression of caspase activity in HTNV N mapped to a highly nonconserved
region from amino acids 270 to 330. In a study by Gupta et al., it was shown that
the ANDV N interacts with caspase 3 and granzyme B, resulting in inhibition of
these apoptosis-inducing enzymes and cleavage of the N protein. Hence,
hantavirus inhibits both granzyme B-mediated activation of caspase 3 and
inhibits activated caspase 3 in infected endothelial cells targeted by natural killer
(NK) cells, thereby protecting infected cells from being killed by cytotoxic
lymphocytes [86]. In ANDV N, the caspase cleavage site mapped to DLID285, a
site that is not conserved across New and Old World hantaviruses [86]. In silico
prediction using GraBCas 1.0 [105] suggests potential caspase and granzyme B
cleavage sites in N from other hantaviruses as well.
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Conclusion
Diseases caused by hantaviruses cause a spectrum of vascular leakage
in endothelial cells within the lung or kidney that can lead to shock and death. At
present, there are no Food and Drug Administration (FDA) approved treatments
and hence continued efforts on the mechanisms hantaviruses use to persist in
their reservoirs and that cause disease in humans are essential to discovery of
effective therapeutics. A number of recent studies show differences among the
Old and New World hantaviruses in several aspects of their life cycle. Further,
studies show there are striking differences in the immune responses following
infection of hantaviruses within the reservoir and human. Despite the enormous
progress that has been made in understanding the pathogenesis and immune
responses of hantaviruses in humans and rodents, there is a large gap in
molecular based knowledge of hantaviral proteins in their structures, functions
and the mechanisms that facilitate the differences in the immune responses.
Importantly, little is known about the specific viral determinants and viral proteinhost interactions that drive these responses.
Significant gaps in knowledge remain in the entry, replication and
assembly strategies used by hantaviruses. Further, structural studies have been
challenging due to difficulty in purification of hantaviral proteins and the lack of a
reverse genetics system, which have limited researchers ability to gain insight
into function. Additionally, the majority of the studies that characterize the
structure and function of hantaviral proteins have been conducted in Vero E6
cells or with viruses produced from Vero E6 cells.
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In the past decade, in vitro primary endothelial and immune cells models
have emerged to study the host responses elicited by hantaviruses in human and
in a few cases rodent reservoirs. It is assumed that the structure and function of
hantaviral proteins are the same within the Vero E6, human, and rodent
reservoir, but further work to confirm similarities and differences remain. New
insight into the virion structure suggests novel Class II mechanisms for binding to
its receptor and assembly based on the tetrameric conformation. How the two
hantaviruses with Cryo-EM structures interact with different receptors, 1 integrin
for TULV, and 3 integrin for HTNV remains to be elucidated. In addition, distinct
requirements for entry and trafficking of New and Old World hantaviruses
suggest differences in these mechanisms. Whether these differences also extend
to rodent reservoir endothelial cells is not known. Finally, recent findings suggest
that hantaviruses regulate TNF-α and INF-induced responses as well as
apoptosis within infected endothelial cells and nearby immune cells.

These

studies also underscore differences in strategies among the hantaviruses in the
use of the N, NSs and/or GN tails in modulating host response. While some N
protein – host protein interactions have been uncovered, additional studies are
needed to define the precise mechanisms across hantaviruses. Finally, studies
show the potential importance of the CTL responses in causing disease and also
in protection depending on the virus. Clear answers await further analysis of the
CTL-response in many more patients across the major hantaviral diseases.
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Future perspective for treatment
Design and development of vaccines and antivirals for treatment of
hantaviral infections remains challenging. Continued advancement of vaccines
and antivirals would be greatly accelerated with knowledge gained from future
research focused on the structure and function of hantaviral proteins during
entry, fusion, replication and assembly. For example, knowledge of the
glycoprotein spike structure will enable insight into neutralization epitopes that
can be incorporated into vaccination technology.

Knowledge of viral sites of

replication and assembly of HTNV within cells will benefit discovery of new
targets for antiviral drug discovery. Furthermore, future efforts that define the
cellular components that interact with viral proteins may reveal potential
therapeutic targets. Using current and newer approaches in structural and
molecular virology, one can begin to unravel sites and mechanisms of binding,
replication and assembly of hantaviruses within cells. These types of studies will
be important in revealing unique aspects of the viral life cycle that have
presumably thwarted the field’s ability to generate recombinant viruses to study
the function of viral proteins.
In addition to understanding the structure and function of hantaviral
proteins, it is clear that unraveling the differences in immune responses in their
reservoirs and humans may shed important light into novel approaches for
treatment of these serious diseases [100]. Breakthroughs in the study of immune
responses of hantaviruses in rodent models will require the active development
of new reagents in lethal models of disease (e.g., hamster) and persistence (e.g.,
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deer mouse). The recent sequencing of hamster and deer mouse genomes is an
important new development in that regard.
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CHAPTER II
THE MURINE MODEL FOR HANTAAN VIRUS-INDUCED LETHAL DISEASE SHOWS
TWO DISTINCT PATHS IN VIRAL EVOLUTIONARY TRAJECTORY WITH OR
WITHOUT RIBAVIRIN TREATMENT

Introduction
We are interested in how hantaviruses adapt, and hence evolve, in a
nonreservoir rodent host. In nature, hantaviruses have high selectivity of infection
for a single reservoir host species. However, phylogenetic analyses clearly show
that spillover and adaptation of hantaviruses to nonreservoir hosts has occurred
throughout the evolutionary history of Hantavirus. Recent evidence suggests
these spillover events have occurred not only across different genera, but also
between different orders of mammals [108-111]. Understanding spillover and the
emergence of new pathogens in new hosts is critical for safeguarding global
health, both wildlife and human. Spillover of pathogens is the first step leading to
the emergence of new strains, new emerging diseases and potentially,
pandemics. Alarmingly, the “spillover” and subsequent adaptation of viruses to
new hosts in nature is an area of biology of which we have little understanding. In
this chapter of my thesis, I evaluated the Hantaan virus in Mus musculus over
time following infection. The goal was to determine if any changes occurred in
the viral genome over time in the presence and absence of ribavirin. We have
24

previously shown that ribavirin increases the mutation rate of Hantaan virus in
vitro. We hypothesized that ribavirin would increase the error rate in vitro and
drive the virus to lethal extinction as observed in vitro [112]. While we did
observe the expected increase in the mutation frequency of the viral genome to
what we observed in vitro, ribavirin appeared to increase the ability of Hantaan
virus to persist. My contribution to the publication was in the analyses of the viral
sequences sampled over time. In the following I give further background than
provided in the manuscript on the evolution and some of the tools one can use to
evaluate evolutionary changes.

Mechanisms of viral evolution
The three major mechanisms of viral evolution include Antigenic Drift
(AGD), Antigenic Shift (AGS) and recombination [8, 113-116]. Each of these
processes have the potential to result in a genetic change in a coding region that
may alter protein function and therefore phenotype. AGD is an intrinsic process
where a gene drifts due to misincorporation of nucleotides/nucleosides in genes
during synthesis of the genome or copy of the genome by the viral polymerase.
This natural rate of mutation has the possibility of producing both silent and
missense mutations. A missense mutation or nonsynonymous mutation can arise
due to the misincorporation of a single nucleotide which results in a codon for a
different amino acid. In RNA viruses the process of misincorporation has
enormous impact on viral evolution, because the viral polymerase (RdRp) has a
high error rate or lower fidelity than found in the vast majority of host cellular
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polymerases. Generally, as the RdRp synthesizes new RNA genomes, the wrong
nucleotide is misincorporated can range from 103-104. For hantavirus with a
genome of approximately 12,000 nucleosides this may results in 1 nucleotide
change per genome per round of replication [8].
AGS is the process in which two viral strains exchange parts or entire viral
gene segments. This is common in segmented viral RNA genomes such as
hantaviruses and influenza viruses. AGS occurs when two virus strains infect the
same host cell and genomes are packaged with a reassortment from the two
viruses. Reassortment has been shown to occur with hantaviruses in natural
wildlife settings [117].
Recombination is similar to AGS except it is the reorganization/orientation
of alleles in a single gene segment which results in a new phenotype. In Europe
a phylogenetic examination of TULV N protein harbored by Microtus arvalis
found in Slovakia revealed two lineages from different regions that arose through
recombination [114].
The three aforementioned mechanisms of viral evolution can be
influenced

by

intrinsic

(within-host)

and

extrinsic

(between-host

and

environmental) factors. Each of these factors can play an important role on the
success or failure of transmission to new hosts and the replication or life cycle
within-host. Both intrinsic and/or extrinsic pressures within a host can promote
and drive the selection of genetic alterations, directly or indirectly. Examples of
extrinsic pressures that can affect transmission rates of viruses among rodent
hosts are any changes in food, predators and water. In the instance of increased
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predators or decreased food there would be changes in biodiversity and
population structures of rodents in that community. In turn this would influence
the number of infections of a single host over time. If the basic reproductive value
(R0) falls below the rate required for maintenance of the virus in nature, the
infection will die out in that population. Alternatively, an increase in the number of
susceptible individuals in the community could drive spread and prevalence. This
extrinsic pressure could be supplied by an increase in food, which can increase
the number of litters per year and hence the rodent population. Population
increases can also result in increased interaction among rodents through
breeding and fighting and thus an increase likelihood of a virus transmission to
occur, in particular, to nonreservoir rodents.
A Genetic Selective Sweep (GSS) occurs when a mutation results in an
amino acid change in the genome that gives rise to a viral phenotype that is more
fit to survive than its peers. A site under diversifying selection may confer a
phenotype to the population that has increased fitness. The newly emerged viral
genotype may not be dominant, however, and until it reaches greater proportions
in the population, the new genotype may not confer its advantage to the overall
population [118]. This is due to the lag time it takes for the newly produced virus
(now under purifying selection) to become the prominent phenotype in the
population. GSS are most of the time due to bottle neck events (due to extrinsic
or intrinsic pressures). The emergence of positively-selected amino acids or
nonsynonymous amino acids can be identified using various bionformatic
approaches and will be reviewed in the following.
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Tools for evaluation of genetic changes in viral genomes
Nonsynonymous amino acid changes are known as positively selected
amino acids. Positively selected amino acids are identified on a site by site (by
codon) basis. A common approach is to search amino acids within a coding
region for nonsynonymous error rate (dN) greater than the synonymous error
rate (dS). If the nonsynonymous error rate (dN) is greater that a synonymous
error rate (dS), or a (dN/dS)>1.0, this suggests positive selection has occurred. In
order to determine what sites are under positive selection the web server
“DataMonkey” can be used to conduct the analysis (http://www.datamonkey.org),
using alignments of the coding regions within a RNA population.
Since 2010 DataMonkey has been used by the scientific community in
over 100,000 analyses for amino acids under selection [119, 120]. The analyses
that DataMonkey conducts are Single Likelihood Ancestor Counting (SLAC),
Mixed Effects Models of Evolution (MEME), Fixed Effects Likelihood (Fel),
internal

Fixed

Effects

Likelihood

(iFel),

&

Fast

Unbiased

Bayesien

AppRoximation (FUBAR) (Table 1) [119, 120]. The SLAC, Fel, and iFel analysis
are directed to finding amino acid sites that may have been affected by purifying
or diversifying selection across multiple sequences in an alignment [119, 120].
iFel is slightly different than Fel in that is restricted to finding amino acid sites
under positive selection in sequences that are within the internal branches of the
Phylogenetic Tree (created by DataMonkey)[119, 120]. MEME is like Fel and iFel
except that it has a less conservative test statistic (ω) which leads to less Type I
error (the incorrect rejection of the null hypothesis) [119, 120]. The FUBAR
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analysis is like MEME in that it has more computing power than SLAC, Fel, and
iFel [119, 120]. FUBAR although can be used to determine positively selected
amino acids in large datasets [119, 120]. When all analysis are conducted
together on the same dataset it is certain that all amino acids under positive
selection are identified and recombination is taken into account [121].
Herein, we have used these approaches to examine the evolution of
Hantaan virus in a mouse model of lethal infection in the presence and absence
of ribavirin. There are two intrinsic pressures afforded by this model. First,
infection of HNTV in this host represents a spillover infection of a nonreservoir
rodent host. The virus is not adapted to this host and hence to survive or persist
as it does in wild mice in nature. Hence, the virus must undergo genetic changes
that would be favorable for survival. Secondly, we used ribavirin. We have shown
that ribavirin increase the mutation frequency of the RdRp in vitro. Hence,
ribavirin alters the intrinsic environment of the virus-host interaction.
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Table 1.
Datamonkey analysis for determining selection
Method
Single Likelihood
Ancestor Counting
(SLAC)
Mixed Effects Models
of Evolution
(MEME)
Fixed Effects
Likelihood
(FEL)
internal Fixed Effects
Likelihood
(iFel)
Fast Unbiased
Bayesien
AppRoximation
(FUBAR)

Description
Identifies Sites in a multiple sequences alignment that
have been affected by positive of negative selection
using likelihood branch lengths, nucleotide, and codon
substitution parameters (dN) and (dS).
Identifies positive, negative and episodic selection
(large proportion of positively selected sites; multiple
positively selected sites within one sequence) at the
level of individual nucleotide sites.
A codon based maximum likelihood test that identifies
sites in a multiple sequences alignment that have been
affected by positive of negative selection. The
parameters (dN) and (dS) for this test are determined
independently for each codon site.
A codon based maximum likelihood test that identifies
sites under positive and negative selection that are
restricted in sequences in the interior branches of the
tree.
Newest codon based maximum likelihood test that
vastly improves speed of analysis. Parameters for this
test are determined independently for each codon site
and across codon sites.
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In vivo model of hantaviral infection
Laboratory animal models of hantaviruses have proven useful for basic
research to study infection and virulence [122-125] and for the discovery of
therapeutics and potential vaccine candidates [126-131]. For example, the wellestablished lethal, suckling mouse model of HTNV infection demonstrated
ribavirin's therapeutic efficacy [129] and provided the impetus for clinical studies
of its efficacy in humans [128, 130]. Ribavirin was recently shown to have
efficacy in vivo in the lethal hamster model of ANDV, a New World hantavirus
[131]. Clinical studies of intravenous ribavirin treatment of HFRS in human cases
caused by HTNV have shown efficacy, with a decrease in occurrence of oliguria
(decreased urine output) and severity of renal insufficiency [130]. No other
treatment is available for either disease.
The study of an antiviral both in vitro and in an animal model of disease
progression is important for a complete understanding of its mechanism of action
and potential for selecting for drug resistance or lethal mutagenesis [132-135].
Lethal mutagenesis is a chemotherapeutic strategy in which one uses a viral
mutagen to promote the lethal accumulation of mutations in an RNA viral
genome. Ribavirin is a potent, broad-spectrum antiviral for many RNA and DNA
viruses in vitro and in vivo [136]. The antiviral activity against several viruses is
due to its ability to competitively inhibit inosine monophosphate dehydrogenase
(IMPDH) [137, 138], a key enzyme in the de novo synthesis of GTP. Additional
targets for its antiviral activity have been shown, including capping [139],
translation efficiency of viral mRNA [140], and a direct suppressive effect on the
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viral polymerase activity [141-143]. Ribavirin can also act as a potent RNA virus
mutagen for several RNA viruses and can cause error-prone replication [135,
144-147]. In addition to targeting the purine metabolic pathway and viral
enzymes, recent studies suggest that ribavirin may act by promoting a type 1
immune response [148]. Specifically, Kobayashi et al. showed that ribavirin can
down modulate interleukin-10 (IL-10)-producing Treg 1 cells, which could inhibit
the

conversion

of

CD4+ CD25− FOXP3− naive

T

cells

into

CD4+ CD25+ FOXP3+adaptive Treg cells to maintain Th1 cell activity [149]. The
role of the ribavirin-induced immune response in acting as a selective pressure
on hantaviral population and evolution has not yet been addressed.
In vitro, we have shown direct effects of ribavirin on HTNV through the
host IMPDH and viral replication [150], which correlates with an increase in
mutations in the vRNA genome [151, 152]. Our studies on the mechanism of
action of ribavirin's potent antiviral activity have also provided insight into the
standing genetic variation and population structure of HTNV [151, 152]. These
studies revealed an increase in the mutation frequency in the viral population,
after which the mutation frequency did not correlate with a dose-dependent
decrease in the level of viral RNA, Plaque Forming Units (PFU), or [RTP]/[GTP].
Intriguingly, even at the highest concentrations of ribavirin-treated cells, the
proportion of HTNV wild-type sequences never dropped below 60% for the target
S-segment sequence used in sampling. These studies suggested that HTNV
could not survive past a critical mutational burden or lethal threshold.
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Based on the findings of our prior studies [151, 152], we sought to test
whether mice infected with HTNV and treated with ribavirin would show an
increase in mutation frequency and demonstrate a lethal extinction threshold.
Specifically, would ribavirin cause extinction as revealed by an increase in viral
mutation rate followed by a steady decrease in titer in vivo? We found that,
surprisingly, untreated, HTNV-infected mice showed an overall apparent
decrease in mutational frequency compared to the previous mutational
frequencies measured for the HTNV seed stock in Vero E6 cells [151, 152]. In
contrast, ribavirin-treated, HTNV-infected mice showed an increased mutational
load. Both populations showed a reduction in specific infectivity over time. These
studies show, for the first time, two distinct evolutionary trajectories for HTNV
within a lethal mouse model of disease in the presence and absence of ribavirin,
as well as evidence for positive selection not previously observed in vitro. In the
ribavirin-treated vRNA population, analyses of rates of nonsynonymous (dN) and
synonymous (dS) substitutions in the S segment revealed a positive selection for
codons within the HTNV N protein gene, while untreated, HTNV-infected mice
showed purifying selection. Furthermore, in contrast to our prior in vitro studies
[151, 152], the increased mutational load did not lead to lethal extinction.
Intriguingly, viral RNA levels remained high in both untreated and treated
populations, with a decrease in the level of infectious virus over time. The levels
of infectious virus produced by the two populations, however, were statistically
significantly different, reflecting a difference in the selective pressure by the host
with and without ribavirin. Importantly, these data reveal that while the virus
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populations within the ribavirin-treated, HTNV-infected mice had a larger
proportion of deleterious mutations leading to a smaller number of infectious
particles, they harnessed the increased mutation rate to also achieve genetic
changes that improved their survival over that of the wild type. Finally, while a
direct analysis of the potential for ribavirin-induced immune responses as an
added selective pressure was not possible in the context of this experiment, the
immune system of the suckling mouse model was assessed at the time point for
ribavirin treatment, which was 11 days postnatal (dpn) or 10 dpi. These studies
showed a responsive innate immune system in these young mice.

Materials and Methods
Cells and viruses
Vero E6 cells (CRL-1586; ATCC) were propagated and used for
production of HTNV strain 76-118 and measurement of virus in tissue samples.
Cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen)
supplemented with 10% fetal bovine serum (FBS), 1% penicillin-streptomycin,
and 1% L-glutamine (Sigma). The titers of virus in the seed stock and in animal
tissues were measured by determining the numbers of PFU per ml, using an
agarose overlay method as described previously[153].

Animal study
ICR suckling mice (Harlan, Prattville, AL) were used for all animal studies
and were individually identified by tattoo. Pregnant mice were housed singly with
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their pups in solid-bottom polycarbonate cages on stainless steel racks in an
environmentally monitored, well-ventilated room. Bedding (P. J. Murphy Forest
Products, Inc., Montville, NJ) was used in the bottom of the cages. Dams were
fed on certified rodent diet 5002 (PMI Feeds, Inc., St. Louis, MO), and tap water
was provided ad libitum during the study periods. Procedures used in this study
were designed to conform to accepted practices and to minimize or avoid
causing pain, distress, or discomfort in the animals and were approved by the
Institutional Animal Care and Use Committee (IACUC) at Southern Research
Institute.
Animals were monitored for a 26-day period following intracranial (i.c.)
challenge with HTNV (strain 76-118). On day 0, each mouse in group 1 received
10 μL DMEM and each mouse in groups 2 and 3 received 10 μL of 1 × 103 PFU
HTNV diluted in DMEM. Beginning at 11 dpn or 10 dpi, each mouse was treated
with ribavirin (MP Biomedical, Inc.) via the intraperitoneal (i.p.) route at 5 μL/g of
body weight (50 mg/kg of body weight) for 15 days. All mice were observed twice
daily throughout the study periods for signs of morbidity and mortality and for
body weight, and detailed observations were recorded daily beginning at −1 dpi.

Isolation of total RNA, cDNA synthesis, and real-time RT-PCR
Briefly, total RNAs from infected tissues were homogenized and extracted
with TRIzol (Invitrogen), and 0.5 μg of total RNA was subjected to a reverse
transcription (RT) reaction with SuperScript III reverse transcriptase (Invitrogen).
The HTNV S-segment vRNA copy number within virus-infected mouse tissues
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was measured with a real-time RT-PCR assay using the comparative threshold
cycle method, i.e., 2−ΔΔCT method [150, 151]. Real-time PCRs were performed in
triplicate for each sample and were prepared with TaqMan universal PCR master
mix (Applied Biosystems).

Sequencing and phylogenetic analyses
cDNAs were cloned and analyzed for each lung tissue as described
previously [151]. Briefly, cDNA prepared as described above was amplified by a
PCR using Phusion High-Fidelity DNA polymerase (Finnzymes Oy, Finland)
following the manufacturer's protocols. Primers HS24 (forward primer; 5′TACTAGAACAACGATGGCAACTATG-3′) and HS1336 (reverse primer; 5′GTGCAAATATGATTGATAATGATTCAGTAG-3′) were used to amplify the open
reading frame of N within the S-segment gene. The amplified product was cloned
into the pCR-4 plasmid (Topo cloning kits for sequencing; Invitrogen) after A
tailing by using Taq polymerase (Promega). On average, 96 colonies per lung
were subjected to colony PCR using the M13 forward and M13 reverse primers
[151]. As a control, the background mutation frequency (inherent in the
amplification process) was measured using the same enzymes and plasmid DNA
encoding the HTNV S-segment cDNA.
SeqScape 2.1 was used to generate the open reading frame (from codons
19 to 430) of the plus strand of the HTNV S-segment forward and reverse
sequences from each of the clones from each lung. The ABI file of each
sequence was evaluated manually, and sequences with inconclusive nucleotides
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(nt) at any position, stop codons, or gaps were removed. Sequences were
exported into fasta file format, aligned by ClustalW in Mega 5.1 [154], and
compared to the published HTNV 76-118 sequence (GenBank accession
number M14626) as well as other sequences to generate phylogenetic trees
[155]. Mutation frequencies for each sample were calculated from the alignment
of individual cDNA sequences with that of HTNV 76-118. Phylogenetic analyses
based on maximum likelihood or neighbor-joining programs were generated from
the ClustalW alignments in Mega 5.1, with 1,000 bootstraps [154].

Ratio of nonsynonymous to synonymous substitution rates
The ClustalW alignments for the mock-treated and ribavirin-treated groups
defined above were analyzed by the Web server Datamonkey [119]. The
sequence sets were analyzed by single-likelihood ancestor counting (SLAC),
fixed-effects likelihood (FEL), internal fixed-effects likelihood (IFEL), mixedeffects model of evolution (MEME), and fast unbiased Bayesian approximation
(FUBAR), using default settings) [119]. Datamonkey removed all identical
sequences, which left 32 and 107 sequences that differed in the mock-treated
and ribavirin-treated groups, respectively. Automatic model selection identified
the HKY85 nucleotide substitution bias model.

Statistical analyses
Statistical analyses of virus loads from the animal study were performed
using R, a language and environment for statistical computing and graphics
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(www.r-project.org/). A set of generalized linear models (GLM) were used to test
the main effects of treatment (mock or ribavirin) and dpi on viral load (given by
vRNA copy number, number of PFU, or number of PFU/vRNA copy) in mice. Full
models including an interaction term were included in the goodness-of-fit
assessments, and all simpler models were considered to define the accepted
model used in interpretation of data. Only data from time points after the ribavirin
course of treatment were included in the analysis (i.e., ≥12 dpi). Day 26 was not
included in the analyses. Best-fit statistical models were selected using loglikelihood ratio estimates and the Akaike information criterion (AIC). In cases
where single effects models were the best fit to explain the data, nonparametric
statistical tests were used to describe the difference between groups. In all
analyses, the type I error rate was set to an α level of 0.05.

Results
Study design
To define the intrahost mutation frequency and population structure of
HTNV following infection in mock- and ribavirin-treated, HTNV-infected mice, we
employed a standard experimental design and lethal murine model of HTNV that
is used to measure antiviral efficacy (Table 2) (12). One-day-old suckling mice
were infected with 1,000 PFU of HTNV, and from 10 to 24 dpi, mice were treated
once per day with 50 mg/kg of ribavirin. Mice were sacrificed as noted in Table 2,
and lung tissues were harvested and flash frozen in liquid nitrogen. At the same
time that this study was conducted, an efficacy study of an analog of ribavirin
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was conducted in parallel [156]. The mean time to death (MTD) and percent
survival in ribavirin-treated, HTNV-infected mice published as part of that study
were 18.5 days and 35%, compared to 15.5 days and 10% survival for untreated,
HTNV-infected mice [156]. In the groups presented in Table 2, the mock-treated,
HTNV-infected mice that survived to day 26 were moribund, and the virus was
below the limit of detection by plaque assay. The day 26 time point was not
included in our analyses.
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Table 2.
Group, treatment and sampling design
DPN*
Group/
Treatment

DPI**

5
4

9
8

11
10

Group 1: No Virus (mock)

13
12

2

Group 2: HTNV

2

2

Group 3: HTNV & RBV

0

0

2

*DPN- days post-natal, **DPI-days post-infection
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15
14

18
17

2

18
18

21
20

22
23

27
26

2

3

5*

2

3

3

1

2

Total
(mice)
6

0

1

3

16

3

0

3

14

Viral titers in lungs in mock- and ribavirin-treated mice
Lung tissue was harvested and analyzed for S-segment vRNA copy
number by real-time RT-PCR and for number of PFU for both mock- and
ribavirin-treated, HTNV-infected mice (Figure 4). In the mock-treated group, the
vRNA copy number increased through day 12 and remained fairly constant in the
few mice that survived from days 14 to 24 (Figure 4A). Similarly, in the ribavirintreated group, the vRNA copy number remained steady from days 14 to 26. GLM
testing and statistical comparison of vRNA levels (days 12 to 20) in the mocktreated and ribavirin-treated groups showed that they differed significantly
(Wilcoxon rank sum test; P= 0.035). These data showed that the ribavirin-treated
group had more vRNA copies on days 12 to 20 than the mock-treated, HTNVinfected mice.
In the mock-treated, HTNV-infected mice, viral titers measured by plaque
assay increased through day 9 (Figure 4B). After day 9, mock- and ribavirintreated, HTNV-infected mice showed similar levels of PFU over time. GLM model
fitting confirmed that the dpi-only model was the best fit to explain the variance in
numbers of PFU, and analysis of variance (ANOVA) showed no significant effect
of treatment (with or without ribavirin) on the number of PFU, controlling for dpi
(P= 0.84).
We calculated and plotted the selective infectivity (number of PFU/vRNA
copy) over time (Figure 4C), as we have found this valuable for comparisons
made across groups and experiments conducted in vitro [151]. Analysis of the
data by GLM showed that treatment only was the best model to explain the
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variation in the data. Therefore, we used a nonparametric Wilcoxon rank sum
test to compare these two groups, ignoring changes over time, to determine if
there was a difference in the PFU/vRNA ratio due to ribavirin treatment. These
data suggest that the specific infectivity for the ribavirin-treated, HTNV-infected
mice was lower than that for untreated mice (P = 0.053). A model of the
probability density for each population is shown in Figure 4D.
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Figure 4. Viral RNA and infectious virus levels in lung tissue of untreated
and ribavirin-treated, HTNV-infected mice. (A) Lung tissue was homogenized
from each animal specimen and divided to measure the copy number HTNV Ssegment vRNA per gram (g) of tissue in mock-treated (open circles) and
ribavirin-treated (solid circles), HTNV -infected mice and (B) the levels of
infectious virus in lung tissue suspension by PFU. Asterisks indicate vRNApositive samples from animals that were moribund, infectious virus from these
animals were below the limit of detection inplaque assays and were eliminated
from the subsequent analyses of selective infectivity. Open squares indicate
untreated, HTNV-infected, but are noted differently since statistical comparisons
did not take these time points into consideration. In (C), the selective infectivity
(PFU per vRNA copy number based on gram of lung tissue) is plotted by days
post-infection for HTNV-infected mice that were treated with DPBS or ribavirin
from 10 to 25 dpi. In (D), smoothed histograms (probability density functions) of
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the selective infectivity for each group, HTNV-infected mice (dashed line) and
HTNV-infected, ribavirin-treated mice (solid line). The Wilcoxon Rank Sum show
that there was a significant reduction in PFU/vRNA in ribavirin-treated mice,
including only samples from 12-25 dpi (p = 0.053).
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Intrahost genetic variation of HTNV in untreated and ribavirin-treated mice
Using a previously standardized approach to measure the mutation
frequency of HTNV [151], estimates of nucleotide and amino acid (aa) mutation
frequencies were made for each viral population in each mouse lung (Table 3).
Briefly, total RNA was isolated, and S-segment cDNAs were PCR amplified,
cloned, sequenced, and aligned using ClustalW. The region cloned was the open
reading frame of the N protein. Changes from the master consensus (HTNV seed
stock) were counted, and the estimated mutation frequency per 10,000
nucleotides or 3,333 amino acids is shown (Table 3). Our prior analyses for
standardization of the method showed that an accurate assessment of mutation
frequency is reached with a sample size of 48 clones for each sample, after
which no change in the proportion of genetic variation or frequency is noted[151].
The number of cDNAs examined for each mouse lung sample is shown in Table
3, after removal of sequences with stop codons, gaps, or poor sequence
information. For this analysis, we used a total of 653 sequences for the ribavirintreated, HTNV-infected group, among which 107 sequences showed nt/aa
differences from the consensus sequence. For the mock-treated, HTNV-infected
group, we used a total of 408 sequences, among which 32 showed nt/aa
differences.
On day 8 post-infection, the estimated standing genetic variation in the
mock-treated animals ranged from 0.51 to 0.84 mutation per 10,000 nt (Table
3; Figure 5). Our previous in vitro estimates show that HTNV has an estimated
average mutation frequency of 1.1 to 1.4 mutations per 10,000 nt in Vero E6 cells
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[151]. In the mock-treated mice, the mutation frequencies of the HTNV population
showed a nearly 2-fold decrease (Figure 5) (P < 0.05). On average, 0.5
mutations per 10,000 nt was estimated overall from days 8 to 23. In contrast, in
HTNV-infected mice treated with ribavirin, the average mutation frequencies from
days 12 to 20 (2.3/10,000 nt) or days 12 to 26 (1.8/10,000 nt) were 3- to 4-fold
higher (P < 0.05) (Table 3; Figure 5).
We further examined the mutational frequency of HTNV in mock-treated
and ribavirin-treated mice by the specific infectivity, i.e., the number of
PFU/vRNA copy (Figure 6). The hatched line in Figure 6A shows the mutation
frequency of approximately 1.1 mutations per 10,000 nt measured in vitro. The
graph shows a flattening of specific infectivity with increased genetic variation in
the population (ribavirin-treated mice). For the mock-treated group, the specific
infectivity falls below this mutation frequency, while more than half of the ribavirin
points fall above this line (Figure 6A). Analysis of these data by a probability
density function showed that the mock-treated, HTNV-infected mice had a sharp
narrow peak with decreased mutations, while the ribavirin-treated group had a
broader and lower peak of distribution (Figure 6B). Levene's test for equal
variance showed that HTNV-infected, mock-treated mice had marginally
significantly more variance than ribavirin-treated animals (P = 0.067) (Figure
6B).
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Table3.
Summary of mock & ribavirin-treated mutation frequencies
Mouse
ID

Day

1007
D8
1009
D8
402
D12
404
D12
504
D12
308
D14
303
D14
407
D17
305
D17
401
D23
TOTAL
1012
D12
1013
D12
1201
D12
1105
D14
1112
D14
1204
D14
1102
D17
1209
D20
1208
D20
1207
D20
1109
D26
1101
D26
1110
D26
TOTAL
1

No. Nt.
1
Changes

Total No.
cDNAs

Nt. Mutation
Frequency
-5
(x10 )
Mock-treated, HTNV-infected
5
48
8.4
2
32
5.1
4
44
7.4
2
45
3.6
4
48
6.7
0
31
0
4
37
8.8
1
43
1.9
2
33
4.9
1
47
1.7
25
408
AVE
5.4
Ribavirin-treated, HTNV-infected
11
43
20.7
2
44
3.7
4
42
7.71
12
117
8.3
4
40
8.1
16
45
28.8
2
35
4.6
10
43
18.8
4
15
21.6
5
47
8.6
23
42
44.3
15
95
12.8
27
45
48.5
135
92
AVE
18.2
2

AA Mutation
Frequency
-5
(x10 )
20.2
7.6
16.6
16.2
15.2
0
6.6
5.6
0
0
12.6
33.9
11.0
23.1
12.4
18.2
37.8
13.9
45.1
64.7
20.7
98.2
28.1
97.1
38.9

based on a 1236 nucleotide (nt) of cDNA; total number of cDNAs analyzed per mouse
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Figure 5. Average intrahost genetic variability of HTNV population in mockand ribavirin-treated mice. Mice were infected with 1000 pfu of HTNV by
intracranial injection on day 1. After ten days, mock vehicle or ribavirin 50 mg/kg
was administrated once per day for 14 days.
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Figure 6. Selective infectivity of animals from untreated and ribavirintreated animals.

(A) The mutation frequencies for individual animals from

mock- and ribavirin-treated infected groups were plotted against their selective
infectivity (PFU/vRNA copy number). The hatched area represents the range of
the starting HTNV seed stock material measured in Vero E6 cells in vitro. (B)
Smoothed histograms (probability density functions) of vRNA mutation frequency
(mutations per 10,000 nt) in tissues of mock- and ribavirin-treated HTNV infected
mice show that RBV-treated animals have higher variance in mutation rate
(Levene’s test, p = 0.067). Smoothing bandwidth for mock- and ribavirin-treated
groups are 0.5 and 1.5, respectively.

49

In Table 4, the amino acid changes from the consensus (HTNV 76-118)
are presented for each mouse in each of the treatment groups by day. A larger
number of amino acid changes (92 in total) was noted in the ribavirin-treated,
HTNV-infected group than in the mock-treated group (16 in total). Of those amino
acids with a change, 29/92 amino acids showed a gain or loss of
negative/positive charge (Table 4). The distribution of amino acid changes along
the protein shows some clustering (Figure 7). The mock-treated group showed
13 of 16 changes in the first half of the N protein. The distribution of amino acid
changes predominated throughout the N protein in the ribavirin-treated group.
Interestingly, a greater percentage (42%) of those changed in the amino and
carboxyl termini (first and last 110 aa) had changes in charge. In contrast, the
central region had many fewer (20 to 30%) changes in charge.
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Table 4.
Amino acid changes within HNTV S-segment in mice

8
8
12

Mouse
ID
1007
1009
402

12
12
14

404
504
308

none
V19E, D80Y, R282K
G63R, Q79H, G196D
n.d.

14
14

303
-

D110G
-

1112
1204

17
17
20

407
305
-

I122T
none
-

1102
1209

20
20
23
26

401
-

none
-

1208
1207
1101

26

-

-

1110

26

-

-

1109

DPI

Amino Acid Changes*
Mock-Treated
E33G, R268Q, I325Fx2
P182S

Mouse
ID
1012
1013
1201
1105

*changes from wildtype HTNV 76-119 consensus sequence

51

Amino Acid Changes*
Ribavirin-treated
R26G, D37G, D59G, G99C,
R156W, A410E
Q55R, V84A
Y265N, A291V, T318I, N423S
A28T, K77R, M140I, K211E,
E277G, L320M
K30R, P174S, H176Y
M95I, L120R, F165R, R267Q,
S333F,
A410G, D415N
A208V, D394N
G72R, M95I, D118N, A212V,
L255F, A330V
K41M, P132L, G204R, R263K
A70T, K245R, E280D, R367K
(A70V,G87E),D59N, E192K,
R197K, A229V, E237G, P243S,
I305T, A344V, D394N
(R68K,P81L,
L246F),(D88N,G99S, A288V),
M188I, D167N, V130I, P182L,
A227V, I193V, A260T, A260V,
M295I, G310E, T318I, A387T
S121N, T142I, R144K, S164L,
Q196H, R199Kx3, C203Y,
P218S, V222L, P248S, A251T,
G257D, T278I, K358E, E425K

Figure 7. Illustration summarizing the locations of amino acid changes in
the HTNV N protein. The amino acid changes from the HTNV wild-type N
protein sequence identified in mock-treated (A) and ribavirin-treated (B), HTNVinfected mice are noted at the top. Corresponding colors reflect changes in
amino acid charge. Functional domains within the N protein that have been
identified in the literature are noted.
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Phylogenetic relationships of sequences
Nucleotide and amino acid alignments were made with 654 sequences
from the ribavirin treatment group and 418 sequences from the mock treatment
group. The consensus sequences from other strains and species of hantaviruses
reported in GenBank were included in the alignment (GenBank numbers are
available upon request). From the alignments, 546 of the 654 ribavirin treatment
group sequences and 386 of the 418 sequences from the mock-treated group
were identical. The best-scoring maximum likelihood trees for mock-treated
(Figure 8A) and ribavirin-treated (Figure 8B) mice, with additional wild-type
sequences from Hantaan viral strains, are presented. As predicted from the
mutation frequencies, the number of sequences showing nucleotide differences
(light blue) and bifurcation was greater in the ribavirin-treated group (Figure 8B)
than in the mock-treated group (Figure 8A). Tests for positive selection are
discussed in the following section.
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A

Figure 8. Maximum likelihood phylogeny of the open reading frame of the
S-segment and wild type HTNV sequences. Phylograms of nucleotide
sequences from mock-treated (A) and ribavirin-treated (B) HTNV-infected mouse
lungs. The evolutionary history was inferred by using the Maximum Likelihood
method based on the Tamura-Nei model [157]. The tree with the highest log
likelihood is shown for each data set. Initial tree(s) for the heuristic search were
obtained automatically by applying Neighbor-Join and BioNJ algorithms to a
matrix of pairwise distances estimated using the Maximum Composite Likelihood
approach, and then selecting the topology with superior log likelihood value. The
tree is drawn to scale, with branch lengths measured in the number of
substitutions per site. The analysis involved 180 nucleotide sequences. Codon
positions included were 1st+2nd+3rd+Noncoding. All positions containing gaps
and missing data were eliminated. There were a total of 1233 positions in the
final dataset. Evolutionary analyses were conducted in MEGA 5 [154].
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Ratio of nonsynonymous to synonymous substitution rates
Intrahost genetic variation of RNA viruses arises due to their intrinsically
high mutation rates, resulting from error-prone replication (i.e., a lack of
proofreading polymerase activity). It is constrained by purifying selection (also
called negative selection), which eliminates new mutations that reduce specific
infectivity relative to that of the ancestral sequence, for example, by decreasing
the ability of an organism with a particular genotype to enter or replicate in a cell.
Selection can also favor new genetic variants, as occurs, for example, in
vivo when novel sequences allow escape from the host's immune response.
Such selection favoring new variation is called positive selection. Whether or not
selection is acting on a sequence and, if so, what type of selection is present can
be detected by comparing the ratios of nonsynonymous to synonymous
substitution rates (the dN/dS ratio).
To test for evidence of sites under positive or negative selection among
sequences from mock- and ribavirin-treated, HTNV-infected mice, the coding
regions of the nucleotide sequences were aligned using ClustalW and analyzed
using the Datamonkey web-based interface to the SLAC, FEL, IFEL, and FUBAR
programs [119, 120]. Each of these models uses different approaches to
estimate the rates of dN and dS at each site. For example, SLAC is a counting
method that may lack power for data sets comprising a small number of
sequences or low divergence, such as in the mock-treated group [158], but it was
included for comparison. Fixed-effects models such as FEL and iFEL directly
estimate dN and dS at each site, in external and internal branches, respectively.
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The FUBAR method estimates the alignment-wide distribution of synonymous (α)
and nonsynonymous (β) substitution rates, whose ratio (ω) is a common
measure of the type of natural selection operating on the gene (ω values of <1
are interpreted as representing purifying selection, ω values of >1 represent
pervasive diversifying selection, and ω values not statistically different from 1
represent neutral evolution) [119, 120]. Having obtained this surface via Markov
chain Monte Carlo sampling, it is then possible to apply an empirical Bayesian
procedure to estimate the posterior distribution of ω at a given site, and thus to
determine which sites are constrained and which ones are evolving adaptively.
The SLAC method did not detect any codons under positive or negative
selection for either the mock- or ribavirin-treated group. FUBAR analyses
detected three codons under pervasive purifying selection in the mock-treated
group (codons 37, 193, and 225), and FEL analyses found the same three
codons under negative selection in the mock-treated group (codons 37, 193, and
225). FEL also found, for the ribavirin-treated group, that codons 71 and 224 had
two negatively selected sites. The iFEL and FUBAR analyses of the ribavirintreated group (Table 5) found two sites with positive selection (A410 and P248)
and two sites with pervasive diversifying selection (F165 and P248).
To explore the potential for episodic selection or a small number of
branches subject to positive selection, we used MEME [159]. MEME models
variable ω values across lineages at an individual site (i.e., each site is treated as
a fixed-effects component of the model). These analyses (Table 5) revealed two
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codons with episodic selection (F165 and P248) within the ribavirin-treated
group, but none within the mock-treated group.
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Table 5.
Summary of MEME, IFEL and FUBAR analyses
Amino acid
F165
A410
P248
identified→
1
-6
MEME
α
5x10
0
n.d.
β
0
0
n.d.
β+
10000
3627
n.d.
-7
p-value
9.88x10
0.0708
n.d.
-9
-9
IFEL
dS
N/A
5x10
5x10
dN
N/A
78.60
95.09
dNIdS
N/A
15720120000
19017460000
p-value
N/A
0.036374
0.0293944
2
FUBAR
α
0.504806
n.d.
0.363532
β
4.97696
n.d.
2.63544
β >α
0.943738
n.d.
0.901973
Emp. Bayes
17.7
n.d.
9.7
factor
1
Legend: n.d.-none detected; episodic diversifying selection, p-values based on Simes’ procedure
2
(0.1 significance level); Pervasive diversifying selection at a posterior probability ≥0.9.
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Discussion
Infection of hantaviruses can lead to persistence in one host without
disease (rodent reservoir), acute infection with rapid clearance in another host
(adult laboratory mice or wild, non-reservoir rodents), or lethal disease in yet
another (humans or suckling mice). Upon accidental infection of humans,
hantaviruses may cause two different illnesses in humans: HFRS and HPS [8,
15, 160]. At present, there are no vaccines or antivirals available by the FDA for
treatment of either disease. However, intravenous ribavirin has been used in
clinical studies in China and Korea [130] for treatment of HFRS and HPS ([161,
162]. While the studies with HFRS show promise for ribavirin as a therapeutic
approach, its use in treatment of HPS is as yet inconclusive. Efficacy studies in
the lethal HPS hamster model of ANDV infection suggest that it does have
potential [163]. Understanding ribavirin's mechanism of action and potential for
selecting for drug resistance in vitro and in vivo is important to a full interpretation
of its efficacy and safety for treatment of diseases caused by hantaviruses.
In this study, we employed a lethal murine model of hantaviral disease
with a prototypic HFRS virus, HTNV, to gain insight into viral replication and
genetic variation over time with and without ribavirin treatment. Our research and
that of others have shown that small molecules such as ribavirin increase the
mutation load of the viral genome, which results in the extinction of the virus in
vitro [135, 144-147, 151]. Improving our understanding of how to drive a virus to
extinction by increasing genetic variation by use of small antiviral molecules such
as ribavirin (e.g., lethal mutagenesis) requires insight into how viruses evolve and
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adapt within different environments. In naturally occurring infection cycles,
changes in the standing genetic variation of viruses can arise during within-host
(e.g., immune pressure, replication, and diversification) and between-host (e.g.,
transmission bottlenecks) processes of infection. Given the large population
sizes and high mutation rates of RNA viruses, they are predicted to be
enormously effective in their evolutionary response to natural selection. However,
RNA viruses rarely show adaptive, positive selection in nature. This may be due
to theoretical and experimental findings that suggest that many RNA viruses
have evolved to replicate near their mutation threshold and hence have a
relatively limited ability to explore the mutational space required for adaptation.
Hence, the concept emerged to use mutagen-increasing small molecules such
as ribavirin to increase the mutation load and cause error catastrophe or lethal
extinction of the virus [135, 164-167]. Error catastrophe is defined as a loss of
genetic fidelity during RNA virus replication that results in a lethal accumulation
of errors. Ribavirin increases the level of genetic variation or mutation load in
hantaviruses, polioviruses, and others in the presence of ribavirin in vitro,
resulting in error catastrophe or lethal extinction once a specific level of mutation
is achieved by the drug [135, 144-147, 151]. Therefore, one might predict that
coupled with normal within-host selection processes, ribavirin would be even
more effective in causing error catastrophe or lethal extinction of the virus in
vivo than in vitro.
Our studies showed an elevation in mutation frequency of HTNV Ssegment sequences in mice treated with ribavirin similar to that we previously
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reported for our in vitro studies [151, 152]. We observed a corresponding decline
in specific infectivity of HTNV over the course of infection in the ribavirin-treated
mice, but we also observed a similar decline in untreated mice (Figure 4). The
biological bases for each were clearly different, since in the ribavirin-treated,
HTNV-infected mice, we noted an increased mutational load and positive
selection, while in the untreated mice, we observed a decreased mutational load
and purifying selection (Tables 3 to 5). Hence, while the difference in phenotype
of the populations showed only a marginally significant P value (Figure 4),
significant changes occurred in the adaptation of the virus within the N protein
(Table 5), in one evolutionary step (Figure 8B versus Figure 8A). Overall, the
population data are consistent with the changes in selective infectivity (ability of a
transcribed poliovirus RNA to produce infectious virus) reported for poliovirus in a
direct test of the importance of mutation load in vitro [145]. In that study, the
ability of poliovirus RNA to produce infectious virus decreased with increased
mutations, and the phenotype became lethal at a specific mutation load.
Intriguingly, we found a decrease in diversity of the vRNA population in the
untreated, HTNV-infected mice, rather than an increase in genetic diversity or
selection of individual adaptive mutations that correlated with enhanced
pathogenesis in the suckling mouse model.
We have few studies to compare our data with regarding the evolution of
viruses in animal models of infection where animals are treated with ribavirin.
Vignuzzi et al. reported an increase in genetic diversity which correlated with
increased pathogenesis of poliovirus in a mouse model treated with ribavirin
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[147]. Studies with foot-and-mouth disease virus (FMDV) showed that ribavirininduced mutagenesis of an FMDV population in vitro resulted in attenuation of
pathogenicity when these viruses were assessed by infection of an in vivo mouse
model [168]. Recently, coxsackie virus B3 has been shown to have a lower
mutational robustness (greater sensitivity to ribavirin) than that of poliovirus [169].
While direct comparison of the mutational robustness of HTNV to the values
reported for poliovirus and coxsackie virus B3 is not possible, the values
obtained in vitro and in this study are probably similar to or higher than those for
poliovirus. The differences in the trajectories of these viruses may reflect unique
solutions in their biological and evolutionary strategies for survival and adaptation
during infection. For example, in contrast to hantaviruses, polioviruses have only
one reservoir, humans, to maintain their reproductive rate, and FMDVs are
maintained among cloven-hoofed animals as reservoirs. Among hantaviruses,
human-to-human transmission has never been observed for HTNV and has been
observed only for ANDV, which is endemic in South America.
In addition to an elevated mutation load in ribavirin-treated mice, the
average branch length is much longer in our phylogeny for ribavirin-treated,
HTNV-infected mice (Figure 9B) than in that for mock-treated mice, indicating
that the changes induced by ribavirin can trigger longer evolutionary pathways.
Numerous gain- or loss-of-negative-charge substitutions were revealed within the
N protein (Table 4) and propagated in the sequence pool, suggesting a selective
pressure of amino acids in the presence of ribavirin. Signatures of adaptation in
these populations, while preliminary, suggest the importance of the viral N
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protein in the adaptive process. This is not surprising, since N is multifunctional
and may interact with at least three host proteins. The N protein has the ability to
interact with host cellular proteins to modulate immune signaling [107] and
apoptosis [106]. The N protein interacts with several host cellular proteins, such
as Daxx, a Fas-mediated apoptosis enhancer [170], the ubiquitin-like modifier
(SUMO-1), and ubiquitin-conjugating enzyme 9 (Ubc9) [171]. The precise
mechanism associated with these interactions involving N in the life cycle of the
virus is as yet unknown.
HTNV populations from mock-treated and ribavirin-treated mice followed
two different types of evolutionary trajectories, evolving under purifying and
positive selection, respectively. Because our data indicate that virus populations
in ribavirin-treated hosts have greater diversity, there are two non-mutually
exclusive potential reasons for this difference. First, the difference in trajectories
could be influenced by changes in selection experienced by the virus that were
caused by ribavirin. For example, ribavirin may change the nature of the mouse
immune response, resulting in different alleles, not present in the ancestor, being
favored when HTNV finds itself in a ribavirin-treated host. Second, the difference
in trajectories could be influenced by ribavirin's documented effect on the supply
of new mutations. Increased mutation rates generated by exposure to ribavirin
may give HTNV access to new, perhaps rare, alleles that would be beneficial in
both treated and untreated hosts. Such universally beneficial alleles may exist
because the HTNV used in this study is naive with regard to this suckling mouse
model and may be far from its potential genetic optimum in this host. Regardless
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of the underlying selective cause, our experiments suggest that although the
viruses within the ribavirin-treated, HTNV-infected mouse virus populations may
suffer from a greater proportion of deleterious mutations, they harness the
increased mutation rate to also achieve genetic changes that improve their
survival over that of the wild type when exposed to a host treated with ribavirin.
In conclusion, the data presented herein suggest that ribavirin promotes a
hypermutable environment that increases the mutation load in HTNV sequences
in mice. Intriguingly, the levels of vRNA were similar in untreated and treated
HTNV-infected mice, which suggests a potential benefit of increased mutational
loads. Furthermore, the positive selection of amino acids in the N protein in the
ribavirin-treated mice, but not the untreated mice, implies that ribavirin can also
change the rate of adaptive evolution. In other words, sequence space not
obtainable in untreated, HTNV-infected mice becomes available with ribavirin.
With the increased availability of next-generation sequencing and reduced costs,
future experiments will also capture other segments of the HTNV and hold
promise to provide additional insights into evolutionary trajectories of additional
virus-host

interactions

(entry-glycoprotein

and

polymerase-replication

interactions). Experimental models of RNA viral evolution have largely been
conducted within continuous cell lines in which viruses are well adapted and by
creation of selection with temperature changes or small-molecule inhibitors of
replication. In vivo approaches are a critical next step toward validation of these
findings and to define the molecular mechanisms that influence zoonotic virus
evolution and adaption in spillover hosts. In the specific case of ribavirin, the in
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vivo mouse model revealed positive selection of amino acids, while the in vitro
studies did not. Future efforts will continue to explore the mechanisms of
selection and adaptation of Hantavirus in vivo to not only promote an
understanding of how to drive lethal extinction therapeutically but also provide
insight into the molecular mechanisms that influence zoonotic virus evolution and
adaption in reservoirs or spillover hosts.
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CHAPTER III
A NEW PRIMARY LUNG MICROVASCULAR ENDOTHELIAL CELL CULTURE
MODEL FROM DEER MOUSE TO STUDY NEW WORLD HANTAVIRUS
INFECTIONS

Introduction
Hantaviruses persistently infect a variety of rodent, mole, vole, shrew, or
bat species with no apparent illness or pathology [8, 65]. Only the rodent-borne
hantaviruses cause disease in humans, although, not all cause disease. The
New World hantaviruses that are associated with HPS have ≤50% mortality,
while Old World hantaviruses that cause HFRS have a mortality ranging from 112% [8]; neither disease has vaccines for prevention or antivirals for treatment in
the United States. In China and Far East Russia, three vaccines are licensed and
used for the treatment of HFRS. The three inactivated vaccines were created
using purified suckling-mouse brains, golden hamster kidney cells or Mongolian
gerbil kidney cells, respectively, and have shown to elicit protective efficacy in
approximately 90% of populations vaccinated [172].
At present, there are at least 24 species of hantaviruses that are each
harbored by a unique rodent reservoir species. The observed host restriction of
rodent-borne hantaviruses is postulated to be due to coevolution over millions of
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years [173-175]. To date, the vast majority of in vitro studies of infection and
mechanism of New World hantaviruses have focused on nonrodent (nonreservoir
host) cell lines such as Vero E6 (African green monkey kidney cells) or primary
human bronchial epithelial cells. While these studies give valuable insight into
interactions of hantaviruses with nonhuman primate and human cells, they are
not appropriate for understanding interactions of the hantaviruses with their
reservoir, mechanisms of host restriction or persistence in nonreservoir rodents.
The availability of a physiologically and genetically relevant in vitro model is
particularly important given the millions of years of coevolution that allow
persistence of hantaviruses without disease. The availability of rodent reservoir
models will provide an important resource to advance our understanding of
hantavirus-reservoir host interplay that results in modulation of host reservoir
signaling pathways results in immune suppression and persistent infection.
The International Committee on Taxonomy of Viruses (ICTV) recognizes
24 species within the genus, Hantavirus, from rodents, bats and shrews. Of these
24, 19 have been isolated; the vast majority of these isolates have been from the
lungs of wild rodents [113, 176, 177], and more recently, from human tissue
using Vero E6 cells [113, 176, 177]. In addition to serving as a vehicle for
isolation of hantaviruses, Vero E6 cells have also been widely used in the
propagation and study of hantaviruses. Recently, research published by Dr.
Jonas Klingström shows that embryonic fibroblast cells from voles can be used to
isolate and propagate PUUV [178]. This is an important advancement since none
of the Vero E6-derived HFRS isolates Hantavirus have been shown to cause
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disease similar to humans in any animal model, including nonhuman primates.
Severe disease has only been demonstrated through intracranial inoculation of
newborn 1 day old mice with HTNV [179].
In 2006, Hooper published the first model of HPS disease in the Syrian
hamster using ANDV [131]. It is unknown at present what genotypic/phenotypic
or protein function that ANDV has as compared to other hantaviruses that
recreate disease. One potential difference of ANDV is that it is the only member
of the Hantavirus documented to transmit person to person [180]. Therefore, we
may reason that ANDV has evolved with less host restriction. In other words,
ANDV may acts more like a generalist than a specialist species, perhaps
allowing it to be isolated in Vero E6 cells without a loss in its virulent phenotype
(in humans). Even so, ANDV was not virulent in nonhuman primates [181].
Several studies have shown that RNA viruses undergo genetic changes when
they spillover into new host environments and that a virus’s fitness in one
environment may not always extended to a different environment, in vitro or in
vivo [182-185]. Understanding how these viruses persist in their rodent reservoir
and adapt to new rodent hosts will provide new insight into why and how
hantaviruses suppress disease in one host yet elicit disease in others. Moreover,
advancements in discovery of antiviral therapeutics and vaccines depend on
better animal models that resemble human disease.
Fortunately, in the past decade the deer mouse, Peromyscus maniculatus,
has gained momentum as a model for several areas of research leading recently,
to the complete sequencing of its genome [186]. For the New World hantaviruses
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the deer mouse has been an important model for the study of SNV infection and
host immune responses. Deer mice infected with SNV have detectable levels of
viral antigen at 5 days post-infection peaking at day 15 in the lung along with
vRNA levels, with no mice showing clinical signs of HPS [81]. SNV infections of
deer mice show chemokine and cytokine repression throughout the course of
infections in the lung, whereas, the spleen showed a significant (p<0.05) increase
in TGFβ and CCL2 (diphasic) and, IL-12, IL-21, IL-23 and CCL5 [81]. Persistent
SNV infections of deer mice have been shown to promote a Treg phenotype by
expression of Fox-p3 and suppression of T-bet and GATA3 (Th1 and Th2 genes)
[91]. The Treg profile was suggested to be due to an increase in TGFβ, whereas
the acute infection showed increases in INFγ and IL-5 [91]. Dr. Sabra Klein’s
laboratory has demonstrated that SEOV infection of primary lung (from Norway
rats), results in an increase in TGFβ in alveolar macrophages but not in lung
microvascular endothelial cells (L-MVEC) [49]. SEOV infection of L-MVEC
infection showed an up-regulation of PD-L1 using western blot but not in alveolar
macrophages [49]. PD-L1 promotes an anti-inflammatory immune response by
inducing CD+4 T cells to Treg cells. In conclusion, these studies show that a
persistent infection of hantavirus in their reservoir hosts are promoted by eliciting
a Treg phenotype with a down-regulated immune response [81, 91].
The lung endothelium is the primary site for hantavirus replication
following infection of the lung in reservoir and nonreservoir host species. We
chose to use L-MVEC to build a physiologically relevant in vitro model of the
rodent reservoir host. Herein, we report the successful isolation and culture of
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primary L-MVEC from deer mice, the reservoir for SNV. We show that L-MVEC
retained expression of the endothelial specific surface receptors, ICAM-2, over
eight passages. We also report the infection of the deer mouse L-MVEC with
SNV, SEOV and BCCV and the cytokine and chemokine expression levels after
infection. Although preliminary, SNV, SEOV and BCCV induced a TGFβ immune
response during infection of deer mouse L-MVEC albeit at different levels.

Materials & Methods
Viruses and deer mice
All viruses were propagated in Vero E6 cells using DMEM (10% FBS, 1%
Pen/Strep and 5 mM L-Glutamine). Viruses used in this study: SNV strain
Convict Creek 107 (CC107, Dr. Jay Hooper, USAMRIID), SEOV strain SR-11,
(Dr. Connie Schmaljohn, USAMRIID) and BCCV (Dr. Christina Spiropoulou,
CDC). Deer mice (Peromyscus maniculatus) were provided by the National
Institute of Health’s (NIH) Rocky Mountain Laboratory. All animals were
euthanized upon arrival at University of Louisville’s Clinical Translational
Research Building (CTRB) vivarium. All in vivo procedures were conducted in
accordance with an approved institutional animal use protocol from University of
Louisville’s IACUC.
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Isolation and culture of lung microvascular endothelial cells (L-MVEC) from
deer mice
A protocol was developed to isolate L-MVEC based on methods outlined
by Hartwell et al., 1998 (Figure 9) [187]. Rodents were euthanized by CO2
asphyxiation and their lungs were excised and placed in transport media (DMEM,
1% penicillin/streptomycin). Lungs were then removed from media and minced
into small pieces using two scalpels. Minced lung pieces were digested in 0.5
mg/mL collagenase A (Sigma) for 1 hr at 37°C, shaking every 15 min. After
incubation, the lung digest was first triturated using a 10 mL syringe (with no
needle) then filtered through a 70-100 m cell strainer. The filtered cells were
centrifuged twice at 100 x g for 10 min at 4°C, resuspended in 5 mL of Complete
Endothelial Cell Culture Media (M1168 media) (Cell Biologics) and plated on a
100 x 20 mm tissue culture dish (CytoOne) (passage 1) coated with 0.2%
Matrigel (BD Biosciences). After incubating for two days at 37°C and 5% CO2,
cells were incubated with a rabbit polyclonal antibody against mouse ICAM-2
(Fitzgerald) bound to magnetic anti rabbit Dynabeads (Invitrogen). ICAM-2 is a
type I transmembrane glycoprotein found in tight adhesion junctions of
endothelial cells. ICAM-2-positive cells were purified by magnetic separation and
washing with Dulbecco’s phosphate-buffered saline (DPBS), without Ca2+ and
Mg2+, followed by seeding on a 0.2% gelatin-coated dish (Figure 9). The LMVEC were subcultured, using 0.25% Trypsin EDTA, at a ratio of 1:2 or 1:5 and
seeded onto 0.2% gelatin-coated dish every 2-3 or 3-4 days, until they reached
85% confluence.
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Figure 9. Illustration of method for isolation of deer mouse L-MVEC. Five
main steps for isolation of L-MVEC from deer mice. Deer mice L-MVEC were
isolated in five steps as follows: (1) Euthanize mice using CO2, extract the lung
and place in transport media; (2) Mince lungs using scalpels and digest minced
lungs in collagenase A for 1 hr at 37°C; (3) Pass collagenase mixture through cell
strainer and centrifuge at 250 x g for 10 min at 4°C, twice; Cells were
resuspended in M1168 media and cultured for 48 hr at 37°C, 5% CO 2 on a 100 x
20 mm tissue culture dish, coated for 1 hr with matrigel 0.2%; (4) ICAM-2
conjugated bead complexes were created by incubating an ICAM-2 (Fitzgerald)
rabbit anti-mouse antibody and a sheep anti-rabbit Dynabead secondary
(Invitrogen) overnight at 4°C with rotation, cells were washed and ICAM-2
antibody bead complexes were incubated on cells for 1 hr at 37°C, 5% CO2 ;
Cells were detached from dish using 0.25% Trypsin EDTA for no more than 2
min; (5) ICAM-2 positive cells were isolated using a magnet and suspended in
M1168 media, three times; Cells were cultured on a 0.2% gelatin-coated dish for
48 hr at 37°C, 5% CO2.
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Fluorescence-Activated Cell Sorting (FACS) analyses
Deer mice L-MVEC were detached from cell culture dishes using 2 mL
0.2% EDTA in DPBS and vigorous pipetting. The resulting cell suspension was
mixed with an equal part FBS and volume was increased to 10 mL with DPBS.
Cells were washed here, and in subsequent steps, by centrifugation at 250 x g
for 10 min at 4°C followed by resuspension in DPBS with 2% FBS (“staining
buffer”). After two washes in staining buffer, polyclonal rabbit anti-mouse ICAM-2
(Fitzgerald) (1:200) was added to 100 µL cells (106 cells) and incubated for 30
min on wet ice. Cells were washed twice as above and resuspended in 100 µL
staining buffer. Fluorescent secondary antibody (1:1000) conjugate was added
and incubated for 30 min in the dark on wet ice (goat-anti rabbit IgG Alexafluor647, Molecular Probes). Cells were washed twice as above and resuspended in
4% paraformaldehyde for 15 min at room temperature in the dark. Cells were
centrifuged and resuspended in 0.2 mL DPBS for analysis on a FACSCalibur
flow cytometer (BD Biosciences).

Single-stained controls were used for

compensation. Data was analyzed with FlowJo (TreeStar, Inc.). Control cells
treated with secondary antibody-alone were used to set the positive population
gate.

Infections and treatment of L-MVEC
Deer mice L-MVEC were seeded in a 6-well plate at 1.75 x 105 cells per
well for 24 hr prior to infection (80% confluence after 24 hr). L-MVEC were
washed with DPBS and infected with 100 µL of Vero E6-derived SNV (CC107) at
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a MOI of 0.06 (1 x 105 PFU/mL) or treated with LPS (3.33 µg/mL) for 1 hr at
37°C, 5% CO2. After infection, 2 mL of M1168 media was added to each well and
infections were allowed to proceed for 48 hr at 37°C with 5% CO2. After 48 hr the
cell culture supernatant, cellular RNA, and cellular protein were collected.

Western blots
Total protein was isolated from deer mice L-MVEC as follows. Cellular
proteins were isolated using Trizol and dialyzed in 0.1% SDS for 23 hr in 10 kDA
molecular weight dialysis tubing. The protein precipitate was suspended in 8 M
urea in Tris-HCl, pH 8.0 in aqueous 1% SDS and aliquoted/stored at -80°C until
analysis. Proteins were separated by 12% Sodium Dodecyl Sulfate (SDS)
Polyacrylamide Gel Electrophoresis (PAGE) and transferred to nitrocellulose or
nytran. Membrane was blocked in 5 mL of blocking solution (5% dry, low fat dry
milk in 1X TBST) and incubated with polyclonal antibody made to SNV N protein
in rabbit (1:500) and polyclonal antibody against calnexin made in rabbit (Abcam)
(1:1000). Primary antibody was detected by incubation with goat anti-rabbit
polyclonal

horseradish

peroxidase

(HRP)-conjugated

secondary antibody

(Abcam) (1:2000) for 1 hr at RT in the dark. Visualization of bands was
conducted using Chemiluminescent HRP substrate (ECL, Invitrogen) followed by
exposure to autoradiographic film.
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Plaque assay
Six-well plates were seeded with 3 x 105 Vero E6 cells per well and
incubated at 37°C, 5% CO2 for 3 days, until confluent [188]. Wells were infected
in duplicate or triplicate with 10-fold serial dilutions of supernatant from deer
mouse infected L-MVEC. Virus and cells were incubated for 1 hr at 37°C, 5%
CO2, with rocking every 15 min. After infection, 2 mL of 1.6% SeaKem Agar
(Cambrex) was added to each well and plates were allowed to incubate upside
down in a foil-covered humidity chamber for 7 or 10 days at 37°C 5% CO 2. A
second SeaKem agar containing 5% neutral red solution (Sigma) was added for
New World viruses (SNV and BCCV) on day 7 post infection and day 10 for Old
World viruses (SEOV). Plates were again incubated in a foil-covered chamber
upside down at 37°C, 5% CO2 for the remaining 3 days. Plates were observed for
plaques twice a day for 3 days after the neutral red agar overlay.

Virus cell-based ELISA
96-well plates of nearly confluent Vero E6 cells, seeded at 20,000 cells
per well and grown at 37°C, 5% CO2 for 3 days, were infected with 2-fold serial
dilutions of supernatant from deer mouse virus-infected cells and incubated for 34 days. After three days, cells were fixed with acetone and methanol (1:4) and
blocked with 5% nonfat milk in DPBS. Human convalescent serum was added to
5% nonfat milk in DPBS and used to identify cells expressing N protein (1:500)
for 1 hr at RT. The primary antibody was detected with a secondary anti-human
HRP-labeled antibody. Plates were developed using substrate 2,2’-Azino bis [3-
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ethylbenzothiazoline-6-sulfonic acid]-diammonium salt (ABTS) (KPL) for 30 min
at RT in the dark and read using a Synergy 4 microplate reader (BioTek) at 405
nm.

Relative expression levels of cytokines, chemokines and quantification of
viral RNA by qRT-PCR
Total cellular RNA was extracted from L-MVEC supernatants using Trizol
(Invitrogen) according to the manufacturer instructions. 1 µg of RNA along with
random hexamer primers were used for cDNA synthesis by Superscript III
Reverse Transcriptase (Invitrogen). For real-time PCR, we used SYBR green
master mix (Invitrogen) and performed reactions in duplicate using 3 μL of cDNA
(33 ng/µl) and a 10 µM of each primer (final concentration 1 µM) in a 10 μL total
reaction volume. Sequence-specific primers used to amplify SNV S-segment
genes were (forward: [5’-GTC TTT GCA TGT GCT CCT GA-3’] and reverse: [5’ATC CCC ATT GAC TGA GTT CG-3’]). Primers used to assess cytokine and
chemokine expression levels were as published by Schountz et al. (Table 6) [81].
The RT-PCR consisted of 1 cycle of 50°C for 5 min and 95°C for 2 min and 40
cycles of 95°C for 30 sec, 60°C for 30 sec using the 7900 Fast Real-Time
System (Applied Biosystems) and data analyzed using SDS Software version
1.4.0. The threshold was automatically set by the instrument and Ct determined.
Viral RNA and chemokine and cytokine mRNA was quantitated using the mean
of the change in Ct values (ΔCt) normalized to the Ct values of glyceraldehyde-3phosphate dehydrogenase (GAPDH) for each sample (2−ΔΔCt).
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Table 6
Primers to assess cytokine and chemokine expression levels
Forward
TGFβ
IL-6
IL-10
INFγ
CCL2
CCL3
GAPDH

Reverse

5'- CGT GGA ACT CTA CCA GAA ATA CAG C -3'

5'- TCA AAA GAC AAC CAC TCA GGC G -3'

5'- GGA GTG GTC GAG AAC CAA GA -3'

5'- CAG TGA GGA ACG TCC ACA GA -3'

5'- TTA GGG TTA CCT GGG TTG CCA AG -3'

5'- CAA ATG CTC CTT GAT TTC TGG GC -3'

5'- ATG CCT TGA AGG ACA ACC AG -3'

5'- CAT GAA GTC GTC CCG TTT CT -3'

5'- CAG ACG TAC ACA AGA AAA CTG GAC C -3'

5'- GTC AAG TTC GCA TTC AAA GGT GC -3'

5'- AGG AAC CCA GAA ACC TCC AT -3'

5'- CAG CAA ACA GCT TGC AGA AG -3'

5'- GGT GCC AAA AGG GTC ATC ATC TC -3'

5'- GCA GGA AGC GTT GCT GAT AAT CTT G -3'
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Results
Isolation and culture of deer mouse L-MVEC.
To achieve insight into the evolution of host switching, I have established
(1) a cell culture model of deer mouse L-MVEC, (2) techniques to infect and
measure SNV and SEOV replication and (3) techniques to measure the
production of infectious particles and host immune responses. Primary L-MVEC
from deer mice were isolated from whole lung extract (digested using
collagenase) using ICAM-2 dynabead conjugated antibody complex (Figure 10).
Isolation of primary deer mice L-MVEC into a 100 x 20 mm dish required 3 deer
mouse lungs from males at 8-12 weeks of age. ICAM-2 positive L-MVEC were
isolated from whole lung extract using magnetic separation. M1168 media was
used to propagate the primary L-MVEC and contains supplements and growth
factors specific for L-MVEC.
Culture conditions were optimized for the L-MVEC model by testing
different flask sizes (T75, T25 and 100 x 20 mm dish), cell passaging ratios (1:2 or
1:5), plate coating solutions and different cell culture media. Specifically cells
were subcultured at a ratio of 1:2 or 1:5, after cells reached 80% confluence.
Morphologically, no changes or loss in the cell number were observed with these
two passaging ratios. We further optimized L-MVEC growth conditions by
comparing culture dish coating methods. We compared growth on dishes coated
with 0.2% Matrigel compared with 0.2% gelatin culture flask; and we noted no
morphological differences. To test for potential differences in growth media, we
grew

L-MVEC

in

M1168

media,

complete
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DMEM

(10%

FBS,

1%

Penicillin/Strptomycin, 5 mM L-Glutamine), Minimal Essential Medium (MEM),
Opti-MEM or Roswell Park Memorial Institute (RPMI) media. All media except
M1168 caused the cells to detach. M1168 media contains growth factors,
hormones, amino acids (essential and non-essential), as well as other
supplements not found in the other media and this media was used in
subsequent infection studies.

Characterization of L-MVEC.
Primary cells can lose viability and phenotype overtime. Assuring the
presence of cellular receptors can be used to characterize the phenotypic quality
of endothelial cells. For endothelial cells, these include ICAM-2, PE-CAM1 and
Ve-Cadherin. Deer mice L-MVEC, at passage 8, were assessed for their ICAM-2
receptor phenotype using FACS.
L-MVEC were detached from the culture dish using 0.2% EDTA. Cells
were incubated with an ICAM-2 primary antibody and an Alexaflour 647
secondary for detection. FACS analysis of deer mouse L-MVEC showed two
fluorescent peaks ICAM-2 positive peaks (Figure 11).

The two peaks

represented by the red line are ICAM-2 positive L-MVEC and the grey region
represents single-stained control cells. The two peaks may be due to; 1) high and
dim populations of staining due to the possibility of more or less secondary
antibody staining per cell, or 2) a high level of background (represented by the
peak in the middle). Single-stained cells were used as controls for the FACS
analysis (represented by the grey shaded peak in Figure 11). In summary, these
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experiments demonstrated that we are successfully able to isolate and propagate
deer mice L-MVEC with an ICAM-2 phenotype for 8 passages (Figure 11).
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A

B

C

D

Figure 10. Deer mouse L-MVEC. (A & B) Images of deer mouse L-MVEC using
phase contrast. Images were taken 24 hr after bead purification (Passage 2) at
400x magnification (McAllister and Jonsson unpublished data). Dynabeads can
be seen as green dots. (B) Blown up lower left region of A. (C & D) Passage 4
and passage 8 –LMVEC at 100x magnification. (C) L-MVEC 24 hr post passage
4, at approximately 50% confluence. (D) L-MVEC 48 hr post passage 8, at
approximately 85% confluence.
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Figure 11. FACS analysis of deer mouse L-MVEC. Passage 8 deer mouse LMVEC. ). FACS analysis using a rabbit anti-mouse ICAM-2 primary antibody
(Fitzgerald Cat. # 70R12192) (McAllister, Camp, and Jonsson unpublished data).
Single stained control L-MVEC are represented by the grey peak whereas,
ICAM-2 labeled L-MVEC are represented by the red line. The red line forms two
peaks indicating two populations of ICAM-2 positive stained cells, which are
either representing background unspecific staining or cells are tagged with
multiple antibodies to ICAM-2 or multiple secondary antibodies are binding to the
primary.
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Permissiveness of deer mouse L-MVEC to SNV hantaviral infection.
Deer mice L-MVEC were infected with Vero E6 propagated SNV (veSNV)
to determine the level of infectious SNV produced from infection and to
determine the amount S-segment replication and N protein translation. The Ssegment encodes for the N protein which is the most abundant produced by
hantaviruses. L-MVEC were infected at a MOI of 0.06 with veSNV for 1 hr in 6well plates. After infection, 2 mL of M1168 media was added to each well and the
plates were incubated for 48 hr at 37°C, 5% CO2. Supernatant was harvested
and stored at -80°C. Total cellular RNA and protein was collected using Trizol
(Invitrogen) according to the manufacture.
Total cellular RNA was isolated from L-MVEC using Trizol according to the
manufacturer and cDNA was synthesized using random hexamer primers. SNV
S-segment specific primers were used for SYBR green qRT-PCR using 100 ng of
cDNA, in which primers were designed to generate a ~100 bp qRT-PCR product.
SYBR green qRT-PCR was used to assess the amount of replication of SNV in
deer mouse L-MVEC by measuring viral S-segment synthesis using the CT2-ΔΔCt
method [148, 151]. We found that SNV S-segment RNA levels were 204-fold
greater in veSNV infected deer mouse L-MVEC as compared to mock (M1168
media)-infected. We can conclude that the primers from SNV are effective for
qRT-PCR analysis, as SNV S-segment has been shown to be increased ~200
fold compared to mock-infected L-MVEC cells (Figure 12). GAPDH was
measured as an endogenous control to standardize cDNA levels using SYBR
green (Figure 12).
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Western blot was employed to determine if SNV N protein was being
translated in the deer mouse L-MVEC. Calnexin was used as an internal cellular
marker and loading control. Our method for extracting cellular proteins was
effective due to the presence of the N protein and calnexin, an endoplasmic
reticulum marker expressed in all cells (Figure 13). We have shown that SNV Ssegment was expressed and N protein was present in SNV infected deer mouse
L-MVEC using Western blot (WB) (Figures 12 & 13).
Supernatant from veSNV-infected deer mice L-MVEC cells was assessed
for the presence of SNV using plaque assay and cell-based ELISA. Serial 10-fold
dilutions of deer mouse L-MVEC SNV supernatant were created to infect Vero
E6 cells in duplicate in a 6-well plate, for 1 hr. After infection, SeaKem agar
overlay was added over the cells to inhibit spread of virus to cells other than
neighbors and plates were incubated for 7 days upside down in a humidity
chamber. After 7 days of incubation a neutral red (Sigma) agar was added to
each well for visualization of plaques over 3 concurrent days. The seed stock,
veSNV, was also quantified to determine if the seed had lost infectivity.
Plaque assays showed no production of SNV in deer mouse infected LMVEC. Viral titers may have been probably below detection of the plaque assay,
given the presence of S-segment RNA and N protein (Figure 12 and 13). One
possible explanation for the lack of visible plaques may be that the viruses were
infecting but not spreading from cell to cell. A second alternative is that the virus
was not making plaques. Plaques are not caused by lysis of cells (for hantavirus)
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but rather lower cell growth. Hence, hantavirus may have no effect on slowing
the growth of deer mouse L-MVEC SNV.
To further ascertain the presence of virus in cells, a cell-based ELISA was
conducted which, also determines the viral titer within the supernatant while not
relying on the formation of plaques by cell growth inhibition. A cell-based ELISA
used 2-fold serial dilutions of virus to infect Vero E6 cells in a 96 well plate, in
quadruplicate, for 3 days. Cells were fixed and stained with primary antibody to N
protein and probed with secondary using the HRP substrate ABTS. Absorbance
readings were conducted with a plate reader at 405 nm, to quantitate positivelyinfected wells. Absorbance values of mock-infected wells were averaged and the
standard deviation of these wells was determined. Positively-infected cells were
identified by having a absorbance value greater than the value determined by the
formula: [((Ave. Abs. Mock) + 3)/(std of Mock)]. Using the cell-based ELISA, we
saw no levels of detectable infection (TCID50/mL) in the deer mouse SNVinfected supernatant (Table 7). We also conducted a cell-based ELISA on the
veSNV and found that the titer was 1 x 102 TCID50/mL. This was surprising due
to the plaque assay titer of 1 x 105 PFU/mL using the same veSNV. We tested
additional viruses for their levels of infection in deer mouse L-MVEC. Vero E6
propagated SEOV (veSEOV) and BCCV (veBCCV) titers were determined to be
106 and 107 PFU/mL, respectively using plaque assay. The titers for the same
veSEOV and veBCCV determined using cell-based ELISA were again lower (104
and 103 TCID50/mL). This suggests that assay requires further development or
optimization.
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Infection of deer mouse L-MVEC was explored using a MOI of 1.0 with
veSEOV and veBCCV. At 48 hours post infection (hpi) we harvested supernatant
and measure the level of infectious virus particles with a cell-based ELISA with
produced 102 TCID50/mL. Interestingly, as with SNV, we were not able to detect
viruses by plaque assay. We do not yet fully understand the difference in titer
between the two assays; especially when considering that the plaque assay is
able to detect more Vero E6 propagated virus than the cell-based ELISA, but not
deer mouse L-MVEC supernatant. One potential explanation is the cell-based
ELISA detects proteins in cells and not those that egress. Hence if there was a
block in egress or spread we would not see plaques, but we would detect
positively stained N antigen using cell-based ELISA. Future efforts will also use
immunofluorescence which is more sensitive that the cell-based ELISA.
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Figure 12. Viral replication of SNV S-segment in infected primary deer
mouse L-MVEC (passage 8). SYBR green qRT-PCR analysis of SNV Ssegment vRNA levels at 48 hpi at a MOI of 0.06 using the comparative CT2-ΔΔCt
method (McAllister, Gerlach, Jonsson unpublished data).
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Molecular Weight (kDA)

Lane Number
#1 #2

Calnexin 90kDa
N protein 49kDa

Figure 13. Deer mouse infected L-MVEC WB analysis. Cellular proteins
extracted from veSNV (CC107) infected deer mouse L-MVEC, 48 hpi at a MOI of
0.06 (McAllister, Adcock, and Jonsson unpublished data). Proteins were
separated by 12% SDS-PAGE, transferred to a nitrocellulose or nytran
membrane and visualized by exposure to autoradiographic film using ECL Novex
ECL HRP Chemiluminescent Substrate Reagent Kit (Invitrogen).
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Table 7.
Cell-based ELISA and plaque assay titers of infected deer mouse L-MVEC at
MOIs of 1 and 0.6, 48 hpi and Vero E6 seed stock viruses

Deer Mouse
Virus

L-MVEC (48 hpi)

Vero E6

Plaque Assay (PFU/mL) Titers
SNV (CC107)

Negative

1 x105

BCCV

Negative

4.6 x 106

SEOV (SR-11)

Negative

2.4 x 107

Mock

Negative

Negative

cell-based ELISA (TCID50/mL)
SNV (CC107)

Negative

1 x 102

BCCV

2.5 x 102

5 x 104

SEOV (SR-11)

1.6 x 102

3 x 103

Mock

Negative

Negative

*Limit of detection 102 PFU/mL or TCID50/mL
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Innate immune signaling profiles mounted by deer mouse L-MVEC when
infected with reservoir and nonreservoir hantaviruses
We will probe for cytokine and chemokine responses produced by deer
mouse L-MVEC during reservoir and nonreservoir hantavirus infections. Prior
studies have shown that during a hantavirus infection of a reservoir host the N
protein can inhibit NFκB translocation to the nucleus thus down regulating TNFαreceptor-mediated-signaling (TNFR) and inhibiting a pro-inflammatory state [104,
106, 107]. In human primary L-MVEC ANDV and PHV show a down regulation of
INF induced Stat1/2 pathways [101]. Cellular chemokines and cytokines upregulate both the JAK-STAT pathway and the TNFR pathway. Also, as discussed
earlier a reservoir infection with SEOV in Norway rat L-MVEC showed
upregulation of PD-L1 which is known to elicit an anti-inflammatory Treg
response [49]. Therefore, we predict that during a reservoir infection (deer mouse
L-MVEC infected with SNV) we expect inhibition of a pro-inflamatory state,
whereas as nonreservoir infection will induce a pro-inflamatory state through the
JAK-STAT and/or the TNFR pathways.
Deer mouse L-MVEC were used to assess the immune response during
veSNV (reservoir virus), veBCCV and veSEOV viral infections [81]. Deer mouse
L-MVEC were infected at a MOI of 1.0 for veBCCV and veSEOV and a MOI of
0.06 for veSNV. Infections were conducted in a 6-well plate for 1 hr. M1168
media was added at a volume of 2 mL per well and the plate was incubated for
48 hr. After infection total cellular RNA was isolated from L-MVEC using Trizol
and cDNA was synthesized using random hexamer primers. Using 100 ng of
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cDNA SYBR green qRT-PCR was used to assess the amount of cytokine and
chemokine mRNA levels in deer mouse L-MVEC using the CT2-ΔΔCt method [148,
151]. GAPDH was measured (using published primers) and used as an
endogenous control to standardize cDNA levels using SYBR green (Figure 12).
Published primer sets, by Shountz et al. 2012, specific to the deer mouse were
used to assess the immune responses.
Our experiment shows that the deer mouse L-MVEC immune response
can be mounted at 48 hpi, after infecting at a MOI of 1.0 for BCCV, and SEOV
(SR-11) and a MOI of 0.06 for SNV (CC107) (Figure 14). At the time of infection
the titer for SNV had yet to be determined so we blindly infected. The positive
LPS showed an increase in TGFβ, IL6, INFγ, and CCL2 (Figure14). This is what
we expected for our positive control, showing that the L-MVEC were capable of
mounting an immune response. TGFβ increased during infection by BCCV and
SEOV and slightly increased for SNV (Figure 14). In contrast to Dr. Klein’s
results with SEOV, TGFβ increased in L-MVEC during infection by BCCV and
SEOV, but not SNV.
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Figure 14. Infected deer mouse L-MVEC innate immune signaling. Gene
expression of deer mouse LMVEC (passage 8) after infection with hantaviruses
(qRT-PCR). L-MVEC were infected with veBCCV, veSNV (CC107), and veSEOV
(SR-11) or treated with LPS (1:1000) for 48 hrs infection at a MOI 1.0 and 0.06
(McAllister, Gerlach, Jonsson unpublished data).
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Discussion
My preliminary data has established a system for probing the evolution
and signaling pathways of hantaviruses within a natural reservoir model. We
have successfully isolated and passaged L-MVEC from deer mice, which
maintained ICAM-2 expression and consistent cell morphologies over 8
passages. For the FACS analysis our result for ICAM-2 expression showed two
peaks. In order to alleviate the result (two peaks), in the future we will perform
titrations of the ICAM-2 antibody to determine the optimal concentration to use.
This will either bring down the fluorescence of 1) the peak possibly representing
the L-MVEC population that are tagged with multiple secondary antibodies (right
red peak) or 2) the middle peak possibly representing L-MVEC population bound
by secondary antibody (not expressing ICAM-2).
Further, we optimized culture conditions for the L-MVEC model that allow
expansion and growth of the cells for use in future studies. In future studies we
will characterize my L-MVEC for the presences of ICAM-2 (CD102), PECAM-1
(CD31) and VE-cadherin (CD144) which are the main surface receptors used to
distinguish L-MVEC from other cells [187, 189-191]. PECAM-1 and VE-cadherin
are tight intracellular junction surface proteins. It has been shown that vascular
leakage of human endothelial cells infected with hantaviruses are negativelycorrelated with VE-cadherin surface expression levels [192]. We will probe for
ICAM-2, PECAM-1 and VE-cadherin L-MVEC surface proteins using FACS,
western blots or microscopy (Table 8) as previously discussed above. The
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positive and negative controls for each characterization experiment are outlined
below (Table 8).
A potential problem of characterizing the deer mouse L-MVEC lies in the
(commercially available) antibody’s cross reactivity to the deer mouse L-MVEC
because these antigens are derived from other mammalian species. If we
continue to encounter this difficulty with any of the chosen antibodies, we will
contact vendors for additional antibodies that are available. We have registered
with AbCAM to provide them information on those we test, and to obtain other
antibodies for the price of one.
During hantaviral infections SEOV showed the greatest increase of TGFβ
which is promising because SEOV is more distantly related to SNV than is BCCV
(which shows the second highest level). TGFβ has been shown to increase
amounts NFκB through up-regulation of TNFα in human cervix epithelial (HeLa)
cells and human lung epithelial (A549) cells [193]. Experiments conducted with
SEOV in Norway rat macrophages showed an increase in TGFβ but not in LMVEC [49]. It is very important to take into account that SNV was used to infect
at a MOI ~20 fold less the MOI that was used for BCCV and SEOV. With that
said SNV would have the highest level of TGFβ even if the fold change (Y-axis,
Figure 7) was multiplied by a factor of 10 (half of the difference in MOI).
Therefore, when taking into account the difference in MOI we can predict that
infection of deer mouse L-MVEC with SNV, at a MOI of 1.0, is capable of
mounting a TGFβ response as published in the literature for reservoir hantavirus
infections.
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Table 8.
L-MVEC characterization approach for FACS or Western Blots/Microscopy

Receptors and Treatment
Group
FACS
WB/M
PECAM-1
ICAM-2
VE-Cadherin
Positive Control 50 ng/mL VEGF [194, NA
NA
(Mouse or Deer 195]
mouse L-MVEC)
Negative
TNFα (100 ng/mL) + TNFα (10 ng/mL) ANDV MOI 1.0
Control
INFγ (1000 U/mL) for 8 + IL1β (34 ng/mL) for 24 hr [192]
(Mouse or Deer hr [194, 196, 197] or for 24 hr [198]
mouse L-MVEC) Trypsin
EDTA
treatment [191]
Test (L-MVEC) No treatment
No treatment
No treatment
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We have shown that we can determine the titer of different hantaviruses
using both plaque assay and cell-based ELISA. We were able to isolate viral
RNA and monitor the expression levels of SNV and SEOV S-segment in deer
mouse L-MVEC through qRT-PCR (SEOV data not shown). We have shown we
are capable of isolating viral and cellular proteins from deer mouse infected LMVEC. These techniques established in my preliminary data will be used in
conjunction with each other for the future goals of my thesis.
The created primer set is effective for monitoring SNV S-segment
replication (Figure 12). Further, we were also successfully able to isolate cellular
proteins from infected deer mouse L-MVEC (Figure 13). In future experiments
will use purified SNV N protein from Vero E6 cells as a positive control (to assess
the primary antibody specificity and to quantify the amount of N protein being
produced). We plan to keep calnexin as the loading control. Although, PFU/mL
titers of BCCV and SEOV infected deer mouse supernatant had lost titer, the
viruses were still detectable using cell-based ELISA (TCID50/mL). The seed virus
(veSNV) suggested a loss in titer, so we plan to regrow the virus seed and
obtained another seed (Table 7). Lastly, the cell-based ELISA and plaque assay
titers obtained for the Vero E6 derived viruses are not the same (Table 7). In
future experiments we will quantify S-segment RNA and N protein amounts,
which will give insight into which method is more accurate at determining the viral
titer of our new in vitro deer mouse L-MVEC model.
Experiments conducted with SEOV in Norway rat macrophages showed
an increase in TGFβ but not in L-MVEC [49]. In our experiments, SEOV showed
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the greatest increase of TGFβ which is promising because SEOV is more
distantly related to SNV than is BCCV (which shows the second highest level).
TGFβ has been shown to increase amounts NFκB through up-regulation of TNFα
in HeLa and A549 cells [193]. It is very important to take into account that SNV
was used to infect at ~16 fold less than the MOI that was used for BCCV and
SEOV. With that said SNV would have the highest level of TGFβ even if the level
was only increased by a factor of 10.

Future Studies
The Hantavirus research community has little understanding regarding the
adaptive steps that result in host switching of hantaviruses. My proposed future
research aims to address this gap in knowledge using our novel, highly relevant
in vitro L-MVEC model from the deer mouse. For future work, we aim to
understand the viral determinants that allow persistence and the host responses
that pose barriers to host adaptation. To achieve this, we plan to adapt the Old
World SEOV to the deer mouse L-MVEC model. Adaptation will be monitored
through viral titer, qRT-PCR of the S-segment and/or western blots of the Nprotein.
Hantaviruses have mostly been isolated from wild rodents and rarely from
human tissue using Vero E6 cells [113, 176, 177]. It is well established that RNA
virus populations can undergo genetic changes from selective pressures in new
host environments and a viruses fitness in one environment may not extended to
a different environment, in vitro or in vivo [182-185]. This is shown for our viruses
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in that SNV propagated in Vero E6 cells are unable to infect deer mouse LMVEC, which is the site the virus has adapted to in nature (Table 6). Therefore,
we plan to first “readapt” the viruses to their natural reservoir L-MVEC model, in
order to have an isolate that resembles what is found in nature. We use the term
“readapt” since our initial studies showed that Vero E6 propagated SNV showed
a very low level of infection and hence, low fitness on deer mouse L-MVEC
(Table 7).
We propose to examine the genetic architecture and fitness of the Vero
E6 propagated SNV and SEOV (veSNV and veSEOV) versus seed stocks
derived from reservoir L-MVEC deer mouse SNV (dmSNV) and Norway rat
SEOV (nrSEOV) L-MVEC. To define the genetic architecture, we will measure
the intrahost population richness by its genetic variability as determined by: (1)
number of different mutations, (2) haplotype number, and/or (3) polymorphic
variability of the entire genome. The diversity of the intra- and inter-host viral
genome populations will be assessed using Shannon entropy, Simpson index
and mutation frequency. We may also explore other approaches that are as yet
unpublished. The sequences of SNV or SEOV isolates will be determined by
Sanger Sequencing of the PCR product to obtain the consensus sequences and
Ultra-deep pyrosequencing (UDPS). Sequences will be analyzed using
Seq.Scape 2.1, Vector NTI, MEGA 5, the Shannon Entropy-Two calculator at Los
Alamos (http://www.hiv.lanl.gov/content/sequence/ENTROPY/entropy. html), and
the web based server Datamonkey.
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Fitness of each virus will be determined by infecting Vero E6 or deer
mouse L-MVEC in triplicate at a low 0.1, mid 0.5, and high 1.0 MOIs with each
virus separately. The ability for each virus to replicate in each cell type will be
determined by measurement of infectious particles (TCID50/mL) released into
supernatant at days 1, 2, 3, and 4 to measure viral titers (or alternatively
PFU/mL). Viral titer will be plotted verses the day and the slope of the linear line
of regression generated, will give the fitness of each virus [199].
After determining the differences between Vero E6 derived hantaviruses
and “readapted” hantavirus, we will test the relationship of extrinsic (new host)
pressures on preexisting intrahost genetic variation and viral fitness using in vitro
models of adaptation (spillover and host-switching). To achieve this, we will use
Norway rat adapted SEOV (nrSEOV) to adapt the virus to deer mouse L-MVEC
(dm-nrSEOV). Adaptation of dm-nrSEOV will be monitored as above using qRTPCR (S-segment), viral titer and N protein levels. We will use CCSS to determine
the censuses sequence of our adapted viruses and UDPS to assess the genetic
architecture and perform infections of Vero E6 and deer mouse L-MVEC to
assess fitness. Lastly, in order to understand the host responses that pose
barriers to host adaptation, we will characterize immune responses elicited in
Vero E6 and deer mouse L-MVEC during infection with veSNV, veSEOV,
dmSNV, nrSEOV, and dm-nrSEOV. The immune response will be assessed
using qRT-PCR, using published primer sets (as discussed). We expect that
viruses replicating in their reservoir will have high fitness and viruses replicating
in their nonreservoir will have low fitness (Table 9). We expect the pro-
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inflammatory immune response to be on during all Vero E6 infection and during
nonreservoir infections of deer mouse L-MVEC (Table 9).

Conclusion
All data presented in Chapter IV is preliminary data characterizing the
New World hantavirus (SNV-deer mouse L-MVEC) model for infection and has
not been repeated. In establishing this model, we have successfully isolated and
passaged L-MVEC cells from deer mice while maintaining ICAM-2 expression
and consistent cell morphologies. We were able to see consistent L-MVEC
morphologies over 8 passages without losing viability or proliferation (Figure 10).
After the initial isolation, ICAM-2 positive L-MVEC were selected using a
magnetic bead secondary antibody (passage 2) (Figure 10 A, B & C). After
further passaging of the L-MVEC to passages 4 and 8, we were able to maintain
ICAM-2 expression and show consistent cell morphology over 8 passages
(Figure 10 D & E).
Hantaviruses are known to be harbored by a single specific reservoir
species for each isolate. The emergence of new hantavirus strains in nature is
due to reassortment and spillover events that occur through rodent to rodent
transmission of hantavirus. There have been limited studies on hantavirus
spillover from their reservoir rodents into nonreservoir rodents, therefore little is
known regarding how host restriction is overcome. The proposed study outlined
in this chapter aims to address gap in our knowledge by adapting nonreservoir
Old World, SEOV to a New World rodent reservoir (deer mouse L-MVEC).
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Knowing which phenotypes are altered and assessing the immune response
elicited during adaptation may provide insights into the host pathways that are
manipulated or avoided by hantavirus during a reservoir infection.
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Table 9
Proposed viruses and predicted phenotypes

Virus
veSNV
dmSNV
veSEOV
nrSEOV
dm-nrSEOV
veSNV
dmSNV
veSEOV
nrSEOV
dm-nrSEOV

Cell Line
Vero E6
Vero E6
Vero E6
Vero E6
Vero E6
Deer mouse L-MVEC
Deer mouse L-MVEC
Deer mouse L-MVEC
Deer mouse L-MVEC
Deer mouse L-MVEC

Fitness
Prediction
H
L
H
L
L
L
H
L
L
H
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Innate Response
Prediction
On
On
On
On
On
On
Off
On
On
Off

Level
M
H
M
H
H
H
L
H
H
L
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Appendix A
LIST OF ABBREVIATIONS
Hantaan Virus
Hemorrhagic Fever with Renal Syndrome
Nephropathia epidemica
Dobrava-Belgrade virus
Seoul virus
Puumala virus
Prospect Hill virus
Hantavirus Pulmonary Syndrome
Adult respiratory Distress Syndrome
Office of the Medical Investigator
Center for Disease Control
Sin Nombre virus
Andes virus
Laguna-Negra virus
Small
Medium
Large
Nucleocapsid
Glycoproteins
RNA dependent Reverse polymerase
Nonstructural Protein
Viral RNA
Complementary RNA
Messenger RNA
Ribonucleoprotein
Cryoelectron Microscopy
Tula virus
Rough Endoplasmic Reticulum
ER-Golgi Intermediate Complex
Black Creek Canal virus
Vascular endothelial growth factor
Bradykinin
Cytotoxic T Lymphocytes
Days post infection
Peripheral blood mononuclear cells
Protein Dependent Ligand 1
Major histocompatibility complex
Regulatory T cells
Foxhead box
T Helper cells
Antigen Presenting Cell
Nuclear Factor Kappa-B
Human immunodeficiency virus
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HTNV
HFRS
NE
DOBV
SEOV
PUUV
PHV
HPS
ARDS
OMI
CDC
SNV
ANDV
LANV
S
M
L
N
GN/GC
RdRp
NSs
vRNA
cRNA
mRNA
RNP
Cryo-EM
TULV
RER
ERGIC
BCCV
VEGF
BK
CTL
dpi
PBMC
PD-L1
MHC
Treg
Fox
TH1 or TH2
APC
NFkB
HIV

Hepatitis B virus
Hepatitis C virus
glycoproteins
New York virus
IFN sequence regulatory element
Natural Killer
Food and Drug Administration
Interferon
Antigenic Drift
Antigenic Shift
reproductive value
Genetic Selective Sweep
Nonsynonymous Error rate
Synonymous Error rate
Single-Likelihood Ancestor Counting
Fixed-Effects Likelihood
Internal Fixed-Effects Likelihood
Mixed-Effects Model of Evolution
Fast Unbiased Bayesian Approximation
((dN) / (dS)) ratio
Inosine Monophosphate Dehydrogenase
Plaque Forming Units
Days postnatal
Dulbecco’s Modified Eagles Medium
Fetal Bovine Serum
Institutional Animal Care and Use Committee
Intracranial
Reverse Transcriptase
Nucleotides
Generalized Linear Models
Akaike Information Criterion
Mean Time to Death
Analysis of Variance
Selective Infectivity
Amino Acid
Foot-and-Mouth disease virus
International Committee on Taxonomy of
Viruses
Lung Microvascular Endothelial cells
Convict Creek 107
National Institute of Health
Clinical Translational Research Building
Complete Endothelial Cell Culture Media
Dulbecco’s phosphate-buffered saline
Facilitated-Activated Cell Sorting
Sodium Dodecyl Sulfate
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HBV
HCV
GPCs
NYV
ISRE
NK
FDA
IFN
AGD
AGS
R0
GSS
(dN)
(dS)
SLAC
FEL
iFEL
MEM
FUBAR
ω
IMPDH
PFU
dpn
DMEM
FBS
IACUC
i.c.
RT
nt
GLM
AIC
MTD
ANOVA
PFU/vRNA
aa
FMDV
ICTV
L-MVEC
CC107
NIH
CTRB
M1168
DPBS
FACS
SDS

Polyacrylamide Gel Electrophoresis
Horseradish Peroxidase
2,2'-Azino bis [3-ethylbenzothiazoline-6sulfonic acid]-diammonium salt
Glyceraldehyde-3-phosphate
Dehydrogenase
Minimal Essential Medium
Roswell Park Memorial Institute
Vero E6 propagated SNV
Western Blot
Vero E6 propagated SEOV
Vero E6 propagated BCCV
hours post infection
TNFα-receptor-mediated-signaling
human cervix epithelial cells
human lung epithelial cell line
deer mouse L-MVEC SNV
Norway rat L-MVEC SEOV
Conventional Cloning Sanger Sequencing
Ultra-Deep Pyrosequencing

…………………...
…………………...

PAGE
HRP

…………………...

ABTS

…………………...

deer mouse L-MVEC adapted nr-SEOV

…………………...

GAPDH
MEM
RPMI
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